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SUMMARY 
 
The physiological role of the cellular prion protein (PrPC) remains enigmatic. Mice 
deficient for PrPC (Prnpo/o) develop normally but are resistant to prion disease.  
However, elucidation of the physiological function of PrPC is of highest importance 
and may be crucial for understanding prion diseases. Expression of amino-terminally 
truncated PrPC (∆PrP) or of its structural homologue Doppel (Dpl) in Prnpo/o mice 
causes cerebellar neurodegeneration and white matter spongiosis. The structural 
similarity between ∆PrP and Dpl and the similar phenotype observed in mice 
expressing these proteins indicate that they trigger neurotoxicity by shared 
mechanisms. By introducing a single allele of Prnp, Dpl as well as ∆PrP-induced 
neurotoxicity was abrogated, suggesting that ∆PrP and Dpl interfere with a cellular 
pathway normally controlled by full-length PrP.  
In the first part of this thesis, we have investigated the mechanisms elicited by 
overexpression of ∆PrP and Dpl in mice leading to white matter pathology and 
cerebellar neurodegeneration.  White matter disease consists of myelin degeneration 
and axonal pathology, which are repressed by selective expression of PrPC in 
oligodendrocytes, suggesting a role for PrPC in axon-myelin interaction and myelin 
maintenance. Consistent with this, we found that PrPC and ∆PrP are present in myelin 
and that, by immunoprecipitating myelin lysates, several myelin proteins specifically 
interact with the full-length as well as the mutant prion protein. MAG, one of the 
PrP-binding myelin proteins, represents the most promising interactor, since it is a 
transmembrane protein that could link the GPI-anchored protein PrP and the 
cytoplasm to transduce the signal elicited by the binding of a ligand to PrP. The 
rescue of the white matter disease by PrPC expression on oligodendrocytes is also 
compatible with the interaction between PrPC and an axonal molecule. To test this 
hypothesis, ∆PrPo mice were crossed with p75NTR deficient mice, since prion protein 
fragment (106-126) has been shown to interact with p75NTR. However, no rescue of 
the pathology in ∆PrPo mice was observed. Therefore, p75NTR does not seem to be 
implicated in ∆PrP induced pathologies.  
In order to study the molecular mechanisms leading to neurodegeneration induced by 
∆PrP and Dpl, we established an in vitro model using primary cerebellar granule cell 
(CGC) cultures from Prnpo/o mice transduced by lentivirus containing the sequences 
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of ∆PrP, Dpl and PrP. No cell death was induced by ∆PrP and Dpl compared to PrP, 
suggesting that expression levels may be insufficient, cell culture conditions may be 
inadequate or CGC death may depend on other cell types.   
 
Prion diseases are characterized by accumulation of a misfolded isoform of the 
cellular prion protein (PrPSc). The precise role of misfolded, aggregated scrapie prion 
protein in the neurodegenerative process remains, however, controversial. 
Biochemical analysis of these aggregates is hampered by the difficulty of processing 
and analyzing proteins prone to aggregation.  
In the second part of this thesis, we have developed a method to solubilize aggregated 
PrPSc, making them directly amenable to proteomic analysis by mass spectrometry. A 
new agent, the anionic detergent sodium 3-[(2-methyl-2-undecyl-1, 3-dioxolan-4-yl) 
methoxyl]-1-propane sulfonate (MPS), proved to be the most effective “solubilizer” 
of PrPSc aggregates. Moreover, the agent is compatible with ICAT technology, 
renders PrPSc PK-sensitive and reduces prion-infectivity titers by several orders of 
magnitude. The effective solubilization of PrPSc aggregates should allow the detection 
of PrPSc associated proteins, which might be important for conversion of PrPC to 
PrPSc. Since mass spectrometry analysis enables femto- to attomole sensitivity and a 
high mass accuracy, this assay could provide the detection of low abundant PrPSc in 
easy accessible material such as urine and blood as well as absolute quantification of 
PrPSc by the use of ICAT labeling, representing new diagnostic tools of prion disease. 
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ZUSAMMENFASSUNG 
 
Die physiologische Bedeutung der normalen, zellulären Form des Prion-Proteins 
(PrPC) ist noch immer unklar. Mäuse, die kein PrPC exprimieren (Prnpo/o), entwickeln 
sich normal, sind aber resistent gegenüber der Infektion mit Prionen. Die Aufklärung 
der physiologischen Funktion von PrPC ist jedoch von grösster Relevanz und könnte 
für unser Verständnis von Prionen-Erkrankungen entscheidend sein. Expression einer 
amino-terminal trunkierten Form von PrPC (∆PrP) oder des strukturellen Homologs 
Doppel (Dpl) in Prnpo/o Mäusen verursacht Neurodegeneration im Kleinhirn und 
Spongiose der weissen Hirnsubstanz. Die strukturelle Ähnlichkeit zwischen ∆PrP und 
Dpl sowie der gleichartige Phänotyp, der durch die Expression von ∆PrP und Dpl in 
Mäusen hervorgerufen wird, legen nahe, dass sie Neurotoxizität über einen 
vergleichbaren Mechanismus induzieren. Die Co-Expression eines Prnp Allels führt 
zur Aufhebung der Neurotoxizität von ∆PrP und Dpl, was bedeuten könnte, dass  
∆PrP und Dpl mit einem zellulären Signalweg interferieren, der normalerweise durch 
PrPC kontrolliert wird.  
Im ersten Teil dieser Doktorarbeit wurden die Mechanismen untersucht, die durch 
Überexpression von ∆PrP und Dpl in Mäusen zu pathologischen Veränderungen im 
Bereich der weissen Substanz und zu zerebellärer Neurodegeneration führen. Die 
Pathologie der weissen Substanz besteht aus einer Degeneration des Myelins sowie 
der Axone, welche durch selektive Expression von PrPC in Oligodendrozyten 
unterdrückt wird, was eine Funktion von PrPC in der Interaktion zwischen Axon und 
Myelin und bei der Myelinerhaltung nahe legt. Damit im Einklang haben wir 
gefunden, dass PrPC und ∆PrP im Myelin vorkommen und dass, bei 
Immunopräzipitationen von Myelin, vier Myelin Proteine spezifisch mit dem 
zellulären und dem mutanten Prion-Protein interagieren. MAG, eines der PrP-
bindenden Myelin-Proteine, ist wohl der vielversprechendste Bindungspartner, weil es 
ein transmembranäres Protein ist, das als Verbindung zwischen dem GPI-verankertem 
Prion-Protein und dem Zytoplasma fungieren und ein Signal weiterleiten könnte, 
welches durch Bindung eines Liganden an PrPC ausgelöst wird. Die Unterdrückung 
der Leukoenzephalopathie durch die Expression von PrPC in Oligodendrozyten könnte 
sich auch durch eine Interaktion zwischen PrPC und einem axonalen Protein ereignen. 
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Wir haben diese Hypothese getestet, indem wir ∆PrPo Mäuse mit p75NTR defizienten 
(p75o/o) Mäuse gekreuzt haben. Es konnte gezeigt werden, dass das Prion-Protein 
Fragment (106-126) mit p75NTR interagiert. Die Pathologie der ∆PrPo Mäuse liess sich 
jedoch durch die Kreuzung mit p75o/o Mäusen nicht beseitigen. Folglich scheint 
p75NTR für die ∆PrP-induzierten Pathologien nicht von Bedeutung zu sein.  
Um die molekularen Mechanismen, die zur zerebellären Neurodegeneration führen, 
untersuchen zu können, haben wir ein in vitro Modell erstellt, in dem primäre 
zerebelläre Körnerzellen von Prnpo/o Mäusen mit Lentiviren, die PrP, ∆PrP und Dpl 
cDNAs enthalten, transduziert wurden. Es wurde jedoch kein Zelltod durch ∆PrP und 
Dpl verglichen mit PrP induziert, was ineffiziente Expressionslevel, inadäquate 
Kulturbedingungen oder Abhängigkeit der CGCs von anderen Zelltypen suggeriert.  
 
Prionen-Erkrankungen sind durch Ablagerungen einer abnorm gefalteten Form des 
zellulären Prion-Proteins (PrPSc; PrP Scrapie) charakterisiert. Die genaue Rolle des 
abnorm gefalteten, aggregierten PrPSc im neurodegenerativen Prozess ist jedoch 
umstritten. Biochemische Untersuchungen dieser Aggregate sind durch die 
Schwierigkeit, aggregierende Proteine zu prozessieren und zu analysieren, behindert.  
Im zweiten Teil dieser Doktorarbeit, haben wir deshalb eine Methode einwickelt, um 
PrPSc Aggregate zu solubilisieren und um sie einer Analyse mittels Massen 
Spektrometrie zugänglich zu machen. Ein neuer Wirkstoff, das anionische Detergens 
Sodium 3-[(2-methyl-2-undecyl-1, 3-dioxolan-4-yl) methoxyl]-1-Propansulfonat 
(MPS), erwies sich als effektivstes Lösungsmittel der PrPSc Aggregate. Ferner ist der 
Wirkstoff mit der ICAT Technologie kompatibel, macht PrPSc PK-sensitiv und 
reduziert den Prion-Infektiositäts-Titer um mehrere Grössenordnungen. Die effiziente 
Solubilisierung der PrPSc Aggregate sollte erlauben, PrPSc assoziierte Proteine zu 
detektieren, welche für die Konversion von PrPC in PrPSc wichtig sein könnten. Da 
Massenspektrometrie femto- bis attomole Sensitivität und grosse Massengenauigkeit 
erlaubt, wird diese Methode vielleicht die Entdeckung geringer Mengen von PrPSc in 
Urin und Blut sowie die absolute Quantifizierung von PrPSc mittels ICAT 
Technologie ermöglichen, was neue Tests für Prionen-Erkrankungen bedeutet.  
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DEFINITIONS 
Adapted from Aguzzi and Weissmann (Aguzzi and Weissmann, 1997) 
 
 
Prion: from proteinaceous infectious only. Agent of transmissible spongiform 
encephalopathy (TSE), with unconventional properties. The term does not have 
structural implications other than that a protein is an essential component. 
 
'Protein-only' hypothesis: Maintains that the prion is devoid of informational nucleic 
acid, and that the essential pathogenic component is protein (or glycoprotein). Genetic 
evidence indicates that the protein is an abnormal form of PrP (PrP* or, perhaps, 
PrPSc). The association with other 'non-informational' molecules (such as lipids or 
glycosamino glycans) is not excluded. 
 
PrPC or PrP-sen: The naturally occurring form of the mature Prnp gene product. Its 
presence in a given cell type is necessary, but not sufficient, for replication of the 
prion. 
 
PrPSc or PrP-res: An 'abnormal' form of the mature Prnp gene product found in 
tissue of TSE sufferers, defined as being partly resistant to digestion by proteinase K 
under standardized conditions. It is believed to differ from PrPC only (or mainly) 
conformationally, and is often considered to be the transmissible agent or prion 
(however, see PrP*). 
 
PrP*: Within the framework of the protein-only hypothesis, PrP* is defined as the 
form of PrP constituting the essential (or only) component of the prion. It may, but 
need not, be identical to PrPSc. 
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GENERAL INTRODUCTION 
  
Prion diseases or transmissible spongiform encephalopathies 
 
Prion diseases (PDs) or transmissible spongiform encephalopathies (TSEs) are rare 
fatal neurodegenerative disorders of humans and animals, encompassing scrapie in 
sheep and goats, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-
Jakob disease (CJD) in humans (Aguzzi et al., 2001). PDs may present as genetic, 
infectious, or sporadic disorders, all of which involve modification of the prion 
protein (PrP).  
They are usually characterized by neuronal loss and spongiform degeneration of the 
brain accompanied by the appearance of activated astrocytes and microglia. Most 
distinctive, however, is the accumulation in the central nervous system of the host-
encoded prion protein that is designated PrPSc, an abnormally folded form of the 
normal cellular prion protein (PrPC). PrPSc can demonstrate properties of classic 
amyloid and form β-sheet rich, insoluble protein deposits that exhibit birefringence 
after staining with the amyloid dye Congo red.  
Therefore, TSEs are often considered another type of amyloid disease such as 
Alzheimer’s or Huntington’s disease. However, prion diseases are unique among 
amyloid diseases in that they are transmissible. Homogenization of brain tissue from 
affected individuals and intracerebral inoculation into another individual of the same 
species will typically reproduce the disease. This important fact was recognized more 
than half a century ago in the case of scrapie (Cuille and Chelle, 1939), a prion 
disease that affects sheep and goats.  
Much evidence suggests that the abnormal form of PrP may be critical in the 
transmission and pathogenesis of TSEs. Indeed, it has been proposed, but not yet 
proven, that an abnormal PrP is the infectious TSE agent or prion (Prusiner, 1982). 
Prions are defined as proteinaceous infectious particle that are devoid of nucleic acid 
and seem to be composed exclusively of PrPSc.  
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Prion diseases in humans 
 
Several types of neurodegenerative syndromes have been recognized as prion diseases 
in humans: Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker 
syndrome (GSS), Kuru, fatal familial insomnia (FFI), and fatal sporadic insomnia 
(FSI). They can be subdivided into three groups - acquired, sporadic, and inherited 
forms. Acquired conditions include diseases transmitted by dietary infections, such as 
Kuru or by other infection routes like iatrogenic contact with infected material during 
brain surgery. Sporadic CJD accounts for the majority of (about 85%) human prion 
disease at an incidence of about 0·4–1·8 cases per 1 million people per year world-
wide, with an equal incidence in men and women (Brandel et al., 2000). The etiology 
of sporadic CJD is unknown, although hypotheses include somatic PRNP mutation, or 
the spontaneous conversion of PrPC into the disease associated PrPSc as a rare event. 
Homozygosity at a common coding polymorphism at codon 129 of PRNP encoding 
either methionine or valine predisposes to the development of sporadic and acquired 
CJD (Palmer et al., 1991).  
About 15% of human prion diseases are associated with autosomal dominant 
pathogenic mutations in PRNP (Doh-ura et al., 1989; Hsiao et al., 1989). These 
diseases include familial CJD, GSS and FFI. How pathogenic mutations in PRNP 
cause prion disease has yet to be resolved; however, in most cases, the mutation is 
thought to lead to an increased tendency of PrPC to form PrPSc. 
The emergence of a variant form of CJD (vCJD) in the United Kingdom in 1996 has 
been causally and experimentally linked to the UK BSE epidemic in the 1980s and 
early 1990s. The finding that BSE is transmissible to different animal species, unlike 
previously characterized prion diseases such as sheep scrapie, has raised enormous 
public health concerns worldwide. Although it is not yet possible to gauge the size of 
a potential vCJD epidemic, preliminary data indicate a significant dietary exposure to 
BSE-infected material in Britain and wider implications of the transmissibility of 
prion diseases.  
Prion diseases typically exhibit a very long latency period between the time of 
infection and the clinical manifestation: this is the reason why these diseases were 
originally thought to be caused by “slow viruses”. From the viewpoint of 
interventional approaches, this peculiarity may be exploitable, since it opens a 
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possible window of intervention after infection has occurred, but before brain damage 
is being initiated. Prions spend much of this latency time executing neuroinvasion. 
During this process, little or no damage occurs to brain, and one might hope that its 
interruption may prevent neurodegeneration. 
 
Prion diseases in animals 
 
Animals TSEs include sheep and goat scrapie, the prototypic animal TSE that has 
been recognized more than 200 years ago, but also transmissible mink encephalopathy 
(Marsh and Hadlow, 1992), chronic wasting disease of mule deer and elk (Williams 
and Young, 1980) and bovine spongiform encephalopathy (BSE). Scrapie has been 
recognized as a disease in sheep for over two centuries, and was the first TSE to be 
shown as experimentally transmissible (Cuille and Chelle, 1939). Sheep and goats are 
susceptible to natural scrapie, and the disease occurs primarily in sheep of breeding 
age. Although the first cases have been described since the 18th century, its potential 
routes for natural infection remain elusive. In Great Britain, a previously 
unrecognized neurological disease in cattle was first defined in 1986: the pathologic 
changes in brains were similar to those characteristic of TSEs. This new form of TSE 
in cows, bovine spongiform encephalopathy (BSE) or mad-cow disease, rapidly 
developed into a major epidemic, primarily in the UK but also in other European 
countries. The emergence of BSE was likely to be caused by transmission of sheep 
scrapie to cattle, through infected feed prepared from rendered carcasses(Wilesmith et 
al., 1988). Chronic wasting disease (CWD) is a prion disease of captive and free-
ranging mule deer and elk. Its spread appears to be enhanced by the abnormal 
population densities found in domestic facilities, although the actual mechanism of 
transmission is unknown. First recognized in captive animals, CWD has now also 
been detected in certain wild deer populations and wild elk. The fact that CWD is 
found in wild ruminants on the same range as cattle and sheep raises concern over the 
possibility that CWD could be transmitted to domestic animals and possibly might 
also pose a risk for human infection similar to BSE.  
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Neuroinvasion 
 
Although the infectious agent is most efficiently propagated through intracerebral 
inoculation, peripheral infection is the natural route of transmission in most prion 
diseases. Oral administration is most probably involved in Kuru, BSE and the new 
variant CJD, while parenteral administration of growth hormone and gonadotropins 
has resulted in iatrogenic CJD. One of the perplexing features of prion diseases is the 
long incubation time from peripheral uptake of prions until the onset of clinical 
symptoms. The incubation time can be, at least in part, attributed to the slow kinetics 
by which prions reach their target organ, the central nervous system (CNS). The 
process by which prions gain access to the CNS is generally referred to as 
neuroinvasion (Aguzzi et al., 2001; Nicotera, 2001), which consists of two distinct 
phases. The first phase involves widespread colonization of lymphoreticular organs 
that is achieved by mechanisms that depend on M-cells (Heppner et al., 2001), 
macrophages (Prinz et al., 2002), B-lymphocytes (Klein et al., 1997; Klein et al., 
1998), follicular dendritic cells (Montrasio et al., 2000) and complement factors 
(Klein et al., 2001). The second phase of neuroinvasion comprises transport of 
infectious prions on or in peripheral nerves, probably belonging to the autonomic 
nervous system, in a PrPC-dependent fashion (Baldauf et al., 1997; Glatzel and 
Aguzzi, 2000). The innervation pattern of lymphoid organs is mainly sympathetic. 
Sympathectomy delays the transport of prions from lymphatic organs to the thoracic 
spinal cord, which is the entry site of sympathetic nerves to the central nervous system 
(Glatzel et al., 2001). Accordingly, the relative distance between FDCs and splenic 
nerves controls the velocity of prion neuroinvasion (Prinz et al., 2003). Direct 
invasion of the central nervous system by nerves might occur after peripheral 
infection (Race et al., 2000). 
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Figure 1. Model of prion neuroinvasion in mice. After peripheral inoculation, prions colonize the 
lymphoreticular system. Possible elements that might contribute to the transport into the 
lymphoreticular system are M cells, macrophages, B cells and dendritic cells. Required elements of 
secondary lymphoid organs for prion replication are functional follicular dendritic cells (FDCs) and B 
cells. In the progress of the disease, prions find access to the central nervous system, probably through 
elements of the autonomic nervous system. Alternatively, direct invasion of the central nervous system 
by nerves might occur after peripheral infection. Central nervous system infection through the blood 
cannot be excluded (Aguzzi et al., 2001). 
 
The pathogenesis of prions 
 
The mechanism of neurodegeneration in prion diseases is still poorly understood, and 
not much is known about the mechanism by which prions actually impair neuronal 
function and cause cell death. PrPSc accumulation in the brain is the hallmark of prion 
diseases, and PrPSc seems to be a major component of the infectious agent. But is 
PrPSc also directly responsible for the devastating CNS pathology typical of prion 
diseases? The essential role of PrPC itself in prion propagation was confirmed when 
Prnp knock out mice were intracerebrally challenged with prions (Weissmann et al., 
1993). They not only lacked any clinical signs of scrapie disease but also showed 
unaffected brains, which did not harbour any infectivity or protease resistant PrP; 
thus, ablation of PrPC abolished prion replication and propagation. At this point it 
could be argued that PrP knockout mice were not affected because ablation of the 
normal host PrP removed the substrate for further conversion into PrPSc. Hence, the 
role of PrPSc-mediated neurotoxicity had to be addressed differently. To achieve a 
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sustained delivery of prions to the “prion-replication defective” brains, neurografts 
were introduced expressing high PrP levels and inoculated them with prions 
(Brandner et al., 1996b). These neurografts not only replicated and accumulated PrPSc 
and prion infectivity, but also delivered substantial amounts of prions to the host 
brain, notably without eliciting any clinical disease or neuropathological sign of 
spongiform encephalopathy. Hence, PrPC is an indispensable substrate to elicit disease 
in the brain, and deposition of prions alone does not support neurodegeneration. In 
addition, depletion of PrPC from neurons of scrapie-infected mice reversed early 
spongiform change and prevented neuronal loss and progression of clinical disease 
(Mallucci et al., 2003). This occurred despite the accumulation of extraneuronal PrPSc 
to levels seen in terminally sick wild-type animals. Therefore, PrPSc aggregates are 
unlikely to fully account for prion pathology.  
 
Protein-only prion hypothesis 
 
The protein-only hypothesis was first outlined in general terms by Griffith (Griffith, 
1967), and formulated in more detail by Stanley B. Prusiner (Prusiner, 1982). It states 
that the partially protease-resistant and detergent-insoluble PrPSc is identical with the 
infectious agent and that the infectious agent is devoid of nucleic acid. Additionally, 
the propagation of the agent is thought to be mediated by PrPSc and to require 
conformational change from PrPC to PrPSc molecules. Although the exact physical 
nature of the infectious agent is still controversial, a wealth of evidence supports this 
hypothesis. The primary amino acid sequence of PrPC is a main determinant of the 
species barrier of prions. Linkage to mutations in the PrPC gene was shown for all 
familial forms of human prion diseases (Prusiner et al., 1990). Mice devoid of PrPC 
(Prnp0/0) are resistant to infection by prions, and PrPC is required for prion spread in 
the central nervous system (Brandner et al., 1996b; Büeler et al., 1993; Büeler et al., 
1992). Moreover, the fact that the infectious agent is largely resistant to heat and 
irradiation also supports the protein-only hypothesis and against a viral hypothesis 
(for review see (Taylor, 2000)). However, the ultimate proof for the protein-only 
hypothesis, the in vitro conversion of recombinant PrPC into infectious PrPSc, has 
turned out to be challenging, even though the cell-free conversion from PrPC to a 
protease-resistant isoform by incubating PrPC with PrPSc can be achieved relatively 
efficiently (Hill et al., 1999; Horiuchi and Caughey, 1999b; Kocisko et al., 1994; 
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Saborio et al., 2001). Only lately, the group of Prusiner reported for the first time the 
conversion of a recombinant truncated mouse prion protein (89-231) (MoPrP (89-
231)) into amyloid fibrils that were infectious. Transgenic mice expressing MoPrP 
(89-231) were inoculated with these fibrils. The mice developed neurological 
dysfunction and brain extracts showed protease-resistant PrP by Western blotting 
(Legname et al., 2004). However, protease-resistance does not always correlate to 
infectivity (Hill et al., 1999; Kocisko et al., 1994; Riesner et al., 1996) and vice versa. 
Moreover, protease-sensitive scrapie prion protein has been reported recently in 
heterogeneous aggregates (Safar et al., 2000; Safar et al., 1998; Tzaban et al., 2002) 
and PrPC may undergo disease-associated, diagnostically important modifications that 
do not lead to protease resistance (protease-sensitive PrPSc, or sPrPSc). 
Another important experiment to prove the protein-only hypothesis involves 
abolishing the structure (and infectivity) of the disease-associated prion protein with 
specific salts, and then attempting to restore infectivity by reforming the original 
structure. This has so far failed (Prusiner et al., 1993).  
 
Conversion of PrPC into PrPSc
 
It has been suggested that PrPSc induces conversion of PrPC into PrPSc by 
conformational change. In order to explain the mechanism by which a misfolded form 
of PrP could induce the refolding of native, normal PrP molecules into the abnormal 
conformation, two distinct models have been postulated: (a) the template assistance or 
'refolding' model, and (b) the nucleation-polymerization or 'seeding' model (Figure 2). 
The first model postulates an interaction between exogenously introduced PrPSc and 
endogenous PrPC, which is induced to transform itself into further PrPSc. A high 
energy barrier may prevent spontaneous conversion of PrPC and PrPSc at detectable 
rates (Gajdusek, 1988; Prusiner et al., 1990). This reaction may involve extensive 
unfolding and refolding of the protein to explain the postulated high energy barrier 
and could be dependent on an enzyme or chaperone, provisionally designated as 
protein X (Telling et al., 1995). In the nucleation model, PrPC and PrPSc are in 
equilibrium strongly favoring PrPC (Come et al., 1993; Jarrett and Lansbury, 1993; 
Lansbury and Caughey, 1995). Only if several monomeric PrPSc molecules are 
mounted into a highly ordered seed, further monomeric PrPSc can be recruited and 
eventually aggregates to amyloid. Within such a crystal-like seed, PrPSc becomes 
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stabilized. Fragmentation of PrPSc aggregates increases the number of nuclei, which 
can recruit further PrPSc and thus results in apparent replication of the agent. 
Consistent with the latter model, cell-free conversion studies indicate that PrPSc 
aggregates are able to convert PrPC into a protease-resistant PrP isoform (Bessen et 
al., 1995; Bessen et al., 1997; Kocisko et al., 1996; Kocisko et al., 1995).  
 
 
 
Figure 2. Models for the conformational conversion of PrPC into PrPSc. A The 'refolding' or 
template assistance model B the 'seeding' or nucleation-polymerization model (Aguzzi and Heppner, 
2000). 
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The prion protein 
Cellular form of the prion protein (PrPC) and its disease-associated 
isoform (PrPSc) 
 
The cellular form of the prion protein (PrPC) consists of 254 amino acids. It is a 
conserved sialoglycoprotein of mainly unknown function, which is usually anchored 
to membranes via glycosyl-phosphatidylinositol (GPI). Nuclear magnetic resonance 
studies have evidenced the structure of the prion protein (Fig.1) (James et al., 1997; 
Riek et al., 1996; Riek et al., 1997; Zahn et al., 2000). It comprises three α-helices 
(amino acids 144-154, 175-193 and 200-219) and a small antiparallel ß-sheet (amino 
acids 128–131 and 161–164). The C-terminal part (i.e. amino acids 126–231) contains 
the complete globular part of the structure, whereas the N-terminus (i.e. amino acids 
23–125) was flexible. Close to the small ß-sheet, a disulphide bridge connects helix 2 
and helix 3. 
 
 
Figure 3. A The three-dimensional structure of a recombinant murine PrPC expressed in Escherichia 
coli. The amino-terminal polypeptide segment 23-120 is flexibly disordered (reprinted from (Korth et 
al., 1997) B Cartoon of the three-dimensional structure of the intact human prion protein, hPrP (23-
230). The helices are red, the -strands cyan, the segments with non regular secondary structure within 
the C-terminal domain yellow, and the flexibly disordered "tail" of residues 23-121 is represented by 
yellow dots (Zahn et al., 2000). 
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In addition, PrPC contains two N-linked complex-type oligosaccharides at positions 
181 and 197. Accordingly, western blot analysis of PrP reveals three major bands, 
reflecting PrP that has two, one, or no glycosylation sites occupied. Glycosylation is 
important as a signal for correct intracellular trafficking of PrPC and possibly also for 
selective targeting of PrPSc to specific brain regions (DeArmond et al., 1999; 
DeArmond et al., 1997). The amino acid sequence of PrPSc is identical to the one of 
PrPC. PrPC is converted into PrPSc through a process that changes its conformation. 
First indications for clear differences in the secondary structure came from 
spectroscopic measurements applying circular dichroism and infrared spectroscopy 
(Caughey et al., 1991; Safar et al., 1993). From those measurements, -helix and ß-
sheet contents could be determined. They show clearly that PrPC is dominated by -
helices and has only little ß-sheet content, whereas PrPSc is characterized by similar 
amounts of -helices and ß-sheets. This structural transition is accompanied by 
profound changes in the physicochemical properties of the prion protein. While PrPC 
is soluble in mild detergents and sensitive to proteinase K (PK) digestion, PrPSc forms 
insoluble aggregates and is partially resistant to PK (Oesch et al., 1985); Meyer, 1986 
#159}. The insolubility of PrPSc impedes its structural analysis by NMR. The PK 
resistance of PrPSc produces an N-terminally truncated form of PrPSc, designated 
PrP27-30 according to its molecular weight on SDS-PAGE. The “full-length” PrPSc is 
cleaved around amino acid 90 and the cleavage product (PrP27-30) is fully infectious 
(McKinley et al., 1991).  
 
Expression pattern of PrPC 
 
The cellular prion protein is highly conserved in mammals and paralogues are present 
in turtle (Simonic et al., 2000), fish (Rivera-Milla et al., 2003; Suzuki et al., 2002) and 
amphibians (Strumbo et al., 2001), suggesting an important function of PrPC. The 
gene encoding the cellular isoform of the prion protein is located on chromosome 20 
in humans and on chromosome 2 in mice. It has been cloned by Charles Weissmann 
and termed Prnp in mouse and PRNP in humans (Basler et al., 1986). In all known 
mammalian and avian Prnp genes, a single open reading frame encodes PrPC. The 
Prnp genes, of mice, sheep and cattle contain three exons, while those of hamsters and 
humans span over two exons (Lee et al., 1998). Within the genome, Prnp is present as 
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a single copy gene and does not show any homologies to other known cellular genes. 
Prnp mRNA is constitutively expressed in the adult organism and developmentally 
regulated during mouse embryogenesis (Manson et al., 1992; Miele et al., 2003). High 
levels of PrPC are expressed in a broad range of tissue and cells including heart, 
skeletal muscle and kidney (Ford et al., 2002b), but its highest expression levels are 
detected in the central nervous system (Ford et al., 2002a). PrPC expression has been 
mostly associated with neurons, particularly with synaptic membranes, although it is 
also expressed by other neural cell lineages like astrocytes and oligodendrocytes 
(Moser et al., 1995). 
 
Biosynthesis of PrPC 
 
Like other membrane proteins, PrPC is synthesized in the rough endoplasmic 
reticulum (ER) and transits the Golgi on its way to the cell surface. During its 
biosynthesis, the N-terminal hydrophobic signal sequence of 22 amino acids guides 
PrP to the membrane of the ER, where it is cleaved off. After translocation, 23 amino 
acids are removed from the C-terminus and a glycosylinositol-phospholipid (GPI) 
anchor is added (Stahl et al., 1987). In the ER, high mannose glycans are attached to 
the 25 kDa polypeptide at two asparagines residues and processed to hybrid or 
complex glycans during the passage through the Golgi apparatus (Bolton et al., 1985). 
The mature PrPC is transported within secretory vesicles to the external cell surface to 
which it is anchored by the GPI-moiety. Recent work has shown that PrPC undergoes 
two posttranslational cleavages as part of its normal metabolism. One cleavage occurs 
within the GPI anchor and releases the polypeptide chain into the extracellular 
medium (Borchelt et al., 1990). The second cleavage is proteolytic and occurs within 
a segment of 16 hydrophobic amino acids that is completely conserved in all cloned 
PrP species (Harris et al., 1993). The physiological significance of the cleavages 
remains speculative. The hypothesis was advanced that, if PrPC functions as a cell 
surface receptor, the cleavages may represent mechanisms of receptor 
downregulation. PrPC does not remain on the cell surface after its delivery there but, 
rather, constitutively cycles between the plasma membrane and an endocytic 
compartment (Caughey et al., 1989; Harris et al., 1996).  
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The physiological function of PrPC
 
The physiological function of PrPC remains elusive. Much hope was pinned on the use 
of PrPC knock-out mice to unveil the function of the protein, but no obvious 
phenotype was observed (Büeler et al., 1992). Even postnatally induced Prnp ablation 
does not elicit any phenotype (Mallucci et al., 2002). Aging mice show demyelination 
in the peripheral nervous system, albeit without clinical symptoms (Nishida et al., 
1999). A number of subtle abnormalities, e.g. abnormalities in synaptic physiology 
(Collinge et al., 1994) and in circadian rhythms and sleep (Tobler et al., 1996), have 
been described in PrP-deficient mice, but their molecular basis is undefined. The only 
definite phenotype of Prnp0/0 mice is their resistance to prion inoculation (Büeler et 
al., 1993).  
Several physiological roles for PrPC have been proposed, in particular cell adhesion, 
signaling, neuroprotection and metabolic functions related to its copper-binding 
properties.  
Cell culture experiments revealed a constitutive internalization process of PrPC from 
the plasma membrane into endocytic organelles, yet most of the protein recycles back 
to the membrane without degradation (Shyng et al., 1993). The existence of a 
recycling pathway suggests that one physiological role of PrPC might be to serve as a 
receptor for uptake of an extracellular ligand. One attractive candidate for such a 
ligand is the copper ion. It has been shown that copper ions at physiologically relevant 
concentrations rapidly and reversibly stimulate endocytosis of PrPC from the cell 
surface (Pauly and Harris, 1998). Moreover, it has been reported that PrPC can bind 
copper ions and possesses superoxide dismutase activity (Brown and Besinger, 1998; 
Brown et al., 1997). Additionally, amino-proximal truncated PrPC seemed to depress 
endogenous dismutase activity (Sakudo et al., 2003), suggesting a role for copper 
binding of the N-terminal octapeptide-repeat segment. However, PrPC does not make 
any measurable contribution to dismutase activity in vivo (Hutter et al., 2003; 
Waggoner et al., 2000).  
Given the localization of PrP as a GPI-anchored protein in rafts or caveolae, it has 
been proposed that PrP, as with other GPI-anchored proteins, could be involved in 
signal transduction (Jacobson and Dietrich, 1999). Crosslinking of PrPC with F(ab)’2 
antibody fragments has been reported to activate Fyn tyrosine kinase (Mouillet-
Richard et al., 2000). Since Fyn is associated with cellular proliferation and cellular 
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survival, cell surface PrP might modulate neuronal survival. However, it was reported 
that PrP-mediated Fyn activation in cerebellar granule neurons might be responsible 
for neurite outgrowth rather than neuronal survival (Chen et al., 2003).  
Other studies indicate that PrPC may interact with components of signal transduction 
pathways, such as Grb2 (Spielhaupter and Schatzl, 2001). Grb2 is an adaptor protein 
that mediates growth factor receptor signals and also plays an important role in 
neuronal survival. Engagement of PrPC with certain antibodies, a PrPC binding peptide 
(Martins et al., 1997) or with a molecule called stress-inducible protein I (STI 1), 
leads to activation of both the cAMP/ protein kinase A and the Erk signaling 
pathways (Chiarini et al., 2002; Zanata et al., 2002). PrPC-mediated activation of the 
cAMP/ protein kinase A (PKA) pathways have a cytoprotective effect in nervous 
tissue (Chiarini et al., 2002). Taken together, these studies clearly support a 
neuroprotective role for PrP through signal transduction events.  
PrP has been shown to interact with the 37 kDa/67 kDa laminin receptor precursor 
(Gauczynski et al., 2001; Hundt et al., 2001; Rieger et al., 1997) and heparan sulfate 
(Warner et al., 2002), supporting a possible role in cell adhesion and/or signaling.  
Maybe PrPC does not possess any intrinsic biological activity, yet it modifies the 
function of other proteins. Multiple PrPC interacting partners have been identified in 
the recent years: the antiapoptotic protein Bcl-2 (Kurschner and Morgan, 1995), 
caveolin (Gorodinsky and Harris, 1995; Harmey et al., 1995), N-CAM (Schmitt-Ulms 
et al., 2001) and neurotrophin p75 receptor (Della-Bianca et al., 2001). None of these 
interactors, however, have yet revealed a functional pathway in which PrPC would be 
involved in vivo. 
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PART I 
 
 
INTRODUCTION 
Amino-terminal truncated PrP 
 
Mice devoid of PrP develop normally but are resistant to scrapie (Büeler et al., 1993; 
Büeler et al., 1992). Introduction of a PrP transgene restores susceptibility to the 
disease. To identify the region of PrP necessary for this activity, PrPC with amino-
proximal deletions were introduced in PrP knockout mice. Ablation of the N-terminus 
up to amino acid 106 (PrP∆21-106) was not deleterious and restored prion 
propagation in Prnp0/0 mice (Flechsig et al., 2000; Shmerling et al., 1998). However, 
PrP lacking amino acid residues 32-121 and 32-134 (PrP∆21-121 and PrP∆21-134) 
caused early onset ataxia and impaired survival (Shmerling et al., 1998). Histological 
analysis of the brains of 2-3 months old animals showed massive pathological 
changes in the cerebellum: cerebellar granule cell degeneration, intense astrocytosis 
and irregularly distributed large vacuoles in the white matter in the pons. Expression 
of N-terminally truncated PrP targeted to Purkinje cells also leads to Purkinje cell loss 
and ataxia (Flechsig et al., 2003), suggesting that the promoter used in the ∆PrP mice 
is not active in Purkinje cells (Chiesa et al., 1998; Fischer et al., 1996). Reintroduction 
of one intact PrPC allele leading to co-expression of a full-length prion protein in both 
models prevented this phenotype. This led to the concept that PrPC and a functional 
homologue (π) were competing for a ligand or a receptor to transduce an important 
signal and that this homologue could take over PrPC function in the absence of PrPC 
explaining the phenotypic paucity in PrP deficient mice. The truncated mutant, having 
presumably the same affinity for the ligand as wild-type PrP, could compete away π 
in a dominant negative fashion but lack functionally competent domains to transduce 
the relevant signal, which would result in neurodegeneration (Fig. 4).   
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Figure 4. Model to explain effects of truncated PrP. PrP is composed of a globular part (dark 
hatched polygon) and a flexible tail (string-and-ball) (Riek et al, 1997) and may interact separately with 
a presumed ligand, “LPrP”, via these two domains, thereby eliciting a signal. The same signal might be 
elicited by the interaction of LPrP with π, a conjectural protein that has the functional properties of PrP 
(top, left) explaining why PrP knockout mice show no phenotype (top, right). The model postulates that 
PrP lacking the flexible tail can interact with LPrP without giving rise to a signal and that it can compete 
efficiently with π, thus acting as a dominant inhibitor of the latter (bottom) (Shmerling et al., 1998).  
 
The doppelgänger of PrP – the protein Doppel (Dpl) 
 
The discovery of Dpl 
 
Different knockout strategies for disrupting Prnp have been employed (Fig. 5). All 
mutant mouse lines lacked significant regions of the Prnp open reading frame (ORF) 
and did not express PrPC, but showed strikingly different phenotypes. The so-called 
Zurich I Prnpo/o mice as well as the Edinburgh Prnpo/o have deletions of two thirds of 
the Prnp ORF (Büeler et al., 1992; Manson et al., 1994). These mice were clinically 
healthy, although displaying discrete neurophysiological changes and demyelination 
of peripheral nerves on aging (Büeler et al., 1992; Collinge et al., 1994; Manson et al., 
1994; Tobler et al., 1996). However, three other PrP knockout lines, Nagasaki (Ngsk), 
RcmO and Zürich II (ZrchII) Prnpo/o, displayed early normal development but late-
onset ataxia accompanied by cerebellar neurodegeneration mainly due to loss of 
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cerebellar Purkinje cells. In contrast to the Zurich I and Edinburgh PrP knockout 
mice, in the Ngsk, Rcm0, and ZrchII lines, not only the ORF, but also parts of intron 2 
and the non-coding flanking regions were disrupted (Li et al., 2000; Moore et al., 
1999; Sakaguchi et al., 1996). 
 
 
Figure 5. Various strategies used to disrupt the locus of the Prnp gene in the creation of different 
strains of Prnp knockout mice. The dotted line indicates the segment of Prnp DNA that has been 
deleted, and the green box indicates a sequence inserted into the gene. Dark red, ORF; pink, non-
coding region; neo, neomycin phosphotransferase; HPRT, hypoxanthine phosphoribosyltransferase; 
lox, a 34-bp recombination site from phage P1 (Weissmann and Aguzzi, 1999). 
 
Since introducing a PrP-transgene prevented the disease, this phenotype was first 
attributed to PrP (Nishida et al., 1999). However, by sequencing of a Prnp-containing 
cosmid, a novel gene 16 kb downstream of Prnp was discovered encoding a 173 
residue protein (Moore et al., 1999). This protein was named Doppel (Dpl) for 
downstream of the prion protein locus and the gene locus, Prnd. It then emerged that 
the gene targeting strategy in all ataxic PrP-deficient mice was associated with 
deletion of a splice acceptor site located on the coding exon of Prnp (Fig. 6). This 
modification effectively placed Dpl under transcriptional control of the Prnp promoter 
(Moore et al., 1999; Sakaguchi et al., 1996). While the Prnp promoter is strongly 
expressed in neuronal cells, the Prnd promoter is not. Therefore Prnd expression from 
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the Prnp promoter results in overproduction of Dpl in the brain, probably being 
responsible for neuronal degeneration. Further experiments have demonstrated an 
inverse correlation between the mRNA levels of Prnd and the onset of ataxia. Disease 
progression is accelerated by increasing Prnd levels, supporting the idea that ectopic 
Dpl expression, but not functional loss of PrPC, might be responsible for neuronal 
degeneration in ataxic Prnp-deficient mice (Rossi et al., 2001). Moore and colleagues 
(Moore et al., 2001) reported that transgenic Prnpo/o mice expressing Dpl ubiquitously 
in brain develop severe ataxia associated with loss of both granule and Purkinje cells. 
The age of onset was inversely proportional to the level of Dpl expression, and 1-
month-old mice were already affected. Introduction of a hamster PrP-encoding 
transgene resulted in complete abrogation of the cerebellar syndrome in animals 
expressing moderate levels, and partial abrogation in animals expressing high levels 
of Dpl.  
 
 
Figure 6. A prion protein's doppelgänger. The Prnp and Prnd loci and expression of the PrP and Dpl mRNAs 
and proteins that they encode. (a) Coding and non-coding exons of Prnp, Prnd, and intergenic exons of unknown 
function. (b) Deletion of the exon of Prnp containing an open reading frame and its flanking regions results in the 
formation of several chimeric mRNAs that comprise the first two exons of Prnp which are spliced directly or 
indirectly to the exon encoding Dpl (Weissmann and Aguzzi, 1999). 
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The structure of Dpl 
 
Dpl is a GPI-anchored protein, expressed on the cell surface (Silverman et al., 2000). 
It displays 23% sequence identity with the C-terminal two thirds of PrPC, but lacks the 
N-terminally located copper-binding octapeptide repeats and the highly conserved 
transmembrane region of PrP (Fig. 6). Contrary to the single disulfide bridge in PrP, 
Dpl has two disulfide bonds. The NMR structure of MoDpl (Mo et al., 2001) as well 
as HuDpl (Luhrs et al., 2003) has recently been resolved: both have an unstructured 
flexible tail at the N-terminus (residues 24-51) and a C-terminal globular domain 
comprising four α-helices and two short β-strand motifs showing a close similarity to 
MoPrP and HuPrP, respectively. Nonetheless, there are differences that may be 
functionally significant.  
The phenotypic proximity and the structural similarity between Dpl and the truncated 
PrP (Fig. 7) suggest that they trigger neurotoxicity by shared mechanisms. By re-
introducing a single allele of Prnp, Doppel as well as ∆PrP induced neurotoxicity 
were abrogated. The mechanism by which Dpl and ∆PrP cause cell death might 
interfere with a cellular pathway normally controlled by full-length PrP.  
 
 
 
Figure 7. Comparison of predicted domains of Dpl with full-length PrP and with PrP in which amino acid 
residues 32 to 134 have been deleted (∆PrP)  (Weissmann and Aguzzi, 1999). 
 
The expression of Dpl 
 
The Prnd gene is evolutionarily conserved, suggesting an essential biological function 
(Aguzzi et al., 2001; Brown et al., 1999; Silverman et al., 2000). It is expressed in a 
more restricted manner than Prnp. By Northern and Western blot analysis, Dpl 
mRNA and protein are found in adult testis and heart, but are absent from the CNS in 
adult wild-type mice (Moore et al., 1999; Silverman et al., 2000). However, 
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significant amounts of Prnd mRNA transcripts have been detected during 
embryogenesis and in the brains of newborn mice, which argues for a possible 
function of Dpl in brain development (Li et al., 2000).  
 
The physiological function of Dpl 
  
To investigate the physiological function of Dpl, mice lacking Dpl were created. 
These mutants develop normally yet suffer from male infertility (Behrens et al., 
2002). These mice show a significant number of malformed and less mobile 
spermatocytes suggesting a deficit in spermatogenesis. Only after partial disruption of 
the zona pellucida was in vitro fertilization of Prndo/o partially restored, therefore 
implicating acromsome malformation as a crucial reason for sterility. These 
experiments revealed a clear function for Dpl in male reproductive system, however 
they provide no information about a possible agonistic or antagonizing functional 
relation with PrPC. Therefore double Prnp/Prnd knockout mice were created (Genoud 
et al., 2004). Mice lacking both PrPC and Dpl (Prno/o) develop normally but suffer 
from male infertility. The absence of compound pathological phenotypes in Prno/o 
mice suggests the existence of alternative compensatory mechanisms. Alternatively, 
Dpl and PrPC may exert distinct function despite having partly overlapping expression 
profiles. 
The role of Dpl in prion pathogenesis was studied by grafting neural stems cells 
homozygous for the disruption of the Prnd locus in the brains of Prnp knockout mice. 
The Prnd null grafts were found to undergo normal neural differentiation, ruling out 
an important function of Dpl during brain development. After inoculation with 
scrapie, grafts lacking Prnd showed unimpaired prion pathogenesis and infectivity 
level similar to wild-type grafts (Behrens et al., 2001). Similarly, overexpression of 
Dpl in the brain of transgenic mice does not modulate prion pathogenesis (Tuzi et al., 
2002). Despite the resemblance of Dpl to N-terminally truncated PrPC protein that 
actually supports PrPSc propagation, Dpl protein seems not to be susceptible to 
conversion into “DplSc”.  
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Outline of this work 
 
Expression of amino-terminally truncated PrPC (∆PrP) or of its structural homologue 
Dpl causes cerebellar neurodegeneration that is prevented by co-expression of full-
length PrP (Shmerling et al 1998; Rossi et al 2001). In addition to cerebellar 
neurodegeneration, ∆PrP expressing mice (∆PrPo mice) as well as Dpl expressing 
mice (Prnpo/ZrchII mice) suffer from white matter spongiosis. Electron microscopic 
analysis revealed myelin splitting and myelin degeneration associated with axonal 
degeneration of mainly large caliber axons, suggesting that ∆PrP and Dpl are 
myelinotoxic. By breeding mice that express PrP under the transcriptional control of 
the neuron specific enolase (NSE) promoter (termed NSE-PrPo mice) and mice that 
express PrP under the transcriptional control of a fragment of the myelin basic protein 
(MBP) promoter (termed MBP-PrPo mice) (Prinz et al 2004) with ∆PrPo mice or 
Prnpo/ZrchII mice, it appeared that cerebellar neurodegeneration and white matter 
disease are two independent phenomena. ∆PrPo; NSE-PrP mice and Prnpo/ZrchII; NSE-
PrP mice exhibit a partial rescue of the cerebellar neurodegeneration. However, white 
matter spongiosis was as severe as in ∆PrPo mice. In the ∆PrPo; MBP-PrP mice and 
Prnpo/ZrchII; MBP-PrP mice exhibit the opposite phenotype: white matter spongiosis 
repression and severe and complete cerebellar neurodegeneration. Theses data 
underline the hypothesis that ∆PrP and Dpl act by the same mechanism to induce 
toxicity.  
To elucidate the mechanism(s) by which ∆PrP and Dpl cause myelin pathology and 
neurodegeneration, we have chosen two different approaches: an in vivo model to 
study the processes leading to axon-myelin degeneration in ∆PrP mice in more detail, 
and an in vitro model to dissect the molecular mechanisms that lead to cerebellar 
granule cell death in mice expressing ∆PrP and Dpl.  
PrP expression in oligodendrocytes specifically rescued the myelinopathy in ∆PrPo 
mice. Therefore physiological oligodendroglial PrPC expression may have an essential 
function in axon-glial interaction and in myelin maintenance. The mechanism leading 
to the rescue of axonal degeneration seems to be non-cell autonomous. ∆PrP and Dpl 
may interfere with this signaling pathway essential for axon-glial interaction and 
myelin maintenance and give rise to the observed leukoencephalopathy. We screened 
myelin lysates for interaction partners of PrP and ∆PrP. Two non-compact myelin 
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proteins, myelin associated glycoprotein (MAG) and 2’3’-cyclic nucleotide 3’-
phosphodiesterase (CNP), and two compact myelin proteins, myelin basic protein 
(MBP) and myelin-associated oligodendrocytic basic protein (MOBP), bound 
specifically to both forms of the prion protein.  
To gain insight into the mechanism of Dpl and ∆PrP induced neurotoxicity, we 
established an in vitro model that is amenable to genetic and biochemical analysis. 
Primary cell cultures of cerebellar granule cells (CGCs) isolated from PrP knock out 
mice were transduced with lentivirus expressing cDNAs of PrPC, Dpl and ∆PrP. 
CGCs were successfully transduced with the different lentiviral constructs. However, 
we did not observe any cell death in cultured cerebellar granule cell death. 
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Possible role of the prion protein in myelin biology 
 
RESULTS 
(A part of these results are submitted in Radovanovic I, Braun N et al, 2004) 
 
Myelinopathy and axonal degeneration in ∆PrPo mice 
 
We found that, in addition to cerebellar granule cell (CGC) degeneration (Fig. 9a), 
mice expressing the amino-terminal truncated PrP (∆32-134) suffer from widespread 
leukoencephalopathy (Fig. 9e). The widespread leukoencephalopathy in terminal sick 
∆PrPo mice (hemizygous for the PrP∆32-134 transgene and devoid of both 
endogenous Prnp alleles) is characterized by coarse vacuolation of the white matter, 
encompassing the intrapontine part of cranial nerves, white matter of the cerebellum, 
the brain stem as well as the anterior and lateral spinal cord columns. On semi-thin 
sections, myelinated fibers in spinal cord and cerebellar white matter displayed severe 
axonal loss associated with large vacuoles, and degeneration of myelin sheath into 
condensed spheroids (Fig 9i). The abnormalities observed in ∆PrPo mice are abolished 
when a wild-type Prnp transgene is introduced (Fig. 9d, h, l). White matter spongiosis 
is not associated with oligodendrocyte cell death or other neuronal cell death than the 
one of cerebellar granule cells (data not shown).  
Electron microscopy analysis revealed axonal swelling containing organelles (Fig. 8 a 
and b). Other axons suffered from compromised adhesion to their myelin sheath, 
evident as periaxonal splitting over broad portions of the axolemma and detachment 
form the myelin wrap (Fig. 8c and d). Many axons had completely degenerated 
leaving behind empty myelin rings or collapsed and condensed residual myelin ghosts 
(Fig. 8e and f). 
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Figure 8. Electron microscopy 
analysis of spinal cord of ∆PrPo 
mice. (a and b) axonal swelling 
and spheroids with accumulation 
of membranous organelles, 
mitochondria and undefined dense 
bodies, (c and d) defects in axon-
glial adhesion,  (e and f) more 
advanced stage of degeneration 
include axonal degeneration  with 
empty myelin rings (arrow) and 
collapse of myelin in condensed 
multilamellar spheroid structures 
(arrowhead) 
 
Rescue of myelinopathy and cerebellar granule cell degeneration 
 
If myelin-producing oligodendrocytes were a primary target of mutant PrPC, selective 
oligodendrocytic expression of PrPC should repress white-matter pathology. ∆PrPo 
were, therefore, bred to tg640 mice, which express full-length PrPC under 
transcriptional control of the MBP promoter (referred to as MBP-PrPo; Prinz et al 
2004). Hemizygous expression of the MBP-PrP transgene in ∆PrPo mice (referred to 
as MBP-PrP; ∆PrPo ) significantly delayed the onset of tremor and ataxia, whereas 
∆PrPo littermates displayed sever wasting and hind limb paralysis. Histological 
analysis showed repression but not complete rescue of axon-myelin degeneration and 
white matter vacuolation (Fig. 9f and j) and absolutely no rescue of CGCs was 
observed (Fig. 9b) in MBP-PrP; ∆PrPo  mice. 
Alternatively, neuronal processes may conceivably represent the primary target of 
mutant PrP toxicity, with myelinopathy being secondary to axonal degeneration. To 
investigate this hypothesis, ∆PrPo mice were crossed to mice expressing full-length 
PrPC under transcriptional control of the neuron specific enolase (NSE) promoter 
(NSE-PrPo mice). NSE-PrPo mice express PrPC in neurons, including CGCs, at higher 
levels than wild-type mice, and do not develop any spontaneous pathological 
phenotype (Giger O, Navaro B and Aguzzi A, unpublished data). ∆PrPo; NSE-PrP 
mice displayed a delayed onset of tremor and ataxia. Histological analysis showed 
repressed cerebellar neurodegeneration (Fig 9c), but revealed leukoencephalopathy of 
similar severity as in ∆PrPo mice (Fig 9g and k). Therefore, white matter disease and 
granule cell degeneration appear to be independent of each other. Co-expression of 
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either oligodendrocyte- or neuron-specific PrPC restored long term survival 
(>500days) with stable or minimally progressing disease in both cases, whereas the 
mean survival time of ∆PrPo littermates was around 100 days. However, only 
ubiquitous expression of PrP completely restored the pathology in ∆PrPo mice (Fig. 
9d, h and l).  
 
 
Figure 9. Myelinopathy and cerebellar granule cell degeneration are independent from each 
other. Cerebellar granule cell degeneration in ∆PrPo mice (a). Neuron-specific expression of PrP rescue 
cerebellar granule cell degeneration (c), while oligodendrocyte specific expression does not (b). 
However, oligodendrocyte specific expression rescues myelinopathy (f), while neuron specific 
expression does not (g). Toluidine blue stained semi-thin sections through spinal cord show axonal loss 
with large vacuoles, and degeneration of myelin sheaths into condensed spheroids in ∆PrPo mice and 
mice that express PrPC selectively in neurons (i and k). ∆PrPo; MBP-PrP mice show degenerated 
myelin spheroids but no vacuolation and an increased number of large caliber axons (j). Co-expression 
of PrP in ∆PrPo mice completely restores the myelin anomalies as well as the cerebellar granule cell 
degeneration (d, h, and l).  
 
No delay or abnormalities in myelination 
 
Axon-myelin pathology may result from developmental myelination failure, or from 
degeneration of myelinated axon following normal development. This question was 
addressed by studying semi-thin spinal cord and cerebellar white matter sections from 
P10 and from P25 ∆PrP+ and ∆PrPo mice, to exclude any delay of initiation of 
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myelination or abnormality in myelination (Fig. 10). We have not observed any delay 
or abnormality in myelination based on toluidine blue semi-thin sections.  
 
 
Figure 10. Neither delay nor abnormalities in myelination in spinal cord or cerebellum of p10 or 
p25 old ∆PrPo mice. Magnification of cerebellum and spinal cord of p10 mice is 1000x, of spinal cord 
from p25 mice is 2000x.  
 
PrPC and ∆PrP are present in purified myelin 
 
Oligodendrocyte-specific expression of PrPC suppresses myelin-axon degeneration in 
∆PrPo mice. If PrPC exerts a function in axon-glial interaction or myelin maintenance, 
it must be present in myelin.  
Myelin was isolated from brains of Prnpo/o, wild-type mice, MBP-PrPo, NSE- PrPo 
and ∆PrPo mice (age: 2-3 months). Significant amounts of PrPC were detected in 
myelin preparations of wt, ∆PrPo and MBP-PrP mice (Fig 11Aa). However, we also 
found PrPC in purified myelin of NSE-PrP mice (Figure 11Aa), whose 
oligodendrocytes do not express PrPC (Fig 11Ba). Poor fractionation with neuronal or 
astrocytic components contaminating the myelin preparation appears to be unlikely, 
since essentially all GFAP and neurofilament proteins, which would be indicative of 
contamination, were removed (Fig. 11Ab and Ac). The presence of PrPC in myelin of 
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NSE-PrP mice, therefore, suggests that axolemmal PrP undergoes high-affinity 
interactions with myelin membrane proteins, as shown for other proteins of the 
myelin-axolemmal complex (Menon et al 2003). Alternatively, neuronally 
synthesized PrPC may be transferred onto myelin sheaths by “cell painting”, which 
was shown to be highly efficient in the case of GPI-linked proteins (Anderson et al 
1996). The strong, low molecular weight bands that can be observed for PrP of the 
MBP-PrPo mice might be due to the degradation of the unglycosylated PrP, because 
glycosylation is known to influence the stability of proteins. The unglycosylated form 
seems to be predominant in myelinic PrPC, similarly to what was observed in MBP-
PrPo mice (Prinz et al 2004).  
 
 
Figure 11. A (a) 10µg of brain homogenate and 5µg of myelin preparation of various genotypes are 
loaded in each lane. Myelin was tested for purity by GFAP (b), marker for astrocytes, and NF, marker 
for neuron (c). B (a) Equal amount of protein of the different oligodendrocyte lysates were loaded  (b) 
actin loading control.  
 
PrPC is localized to the oligodendrocyte plasma membrane 
 
PrPC is a GPI-anchored protein that is processed through ER and Golgi and localizes 
into lipid rafts (Meier et al., 2003; Naslavsky et al., 1997). Since rafts are essential 
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features of all organellar membranes (Mayor and Riezman, 2004), other organellar 
membranes than myelin might co-purify during myelin isolation and could be 
responsible for the presence of PrPC in myelin. Therefore, we analyzed the myelin 
preparations for the presence of Golgi components or ER components by specific 
markers. As figure 12a shows, no marker for either of them were present in the myelin 
membrane preparation. In addition, treatment of myelin membranes with PIPLC 
confirmed the presence of PrP in the myelin membrane. NCAM-120, another GPI 
anchored protein and major NCAM isoform in the myelin (Bartsch, 2003), is also 
released into the supernatant upon treatment with PIPLC. MAG, however, a 
transmembrane protein exclusively found in the myelin sheaths of both 
oligodendrocytes and Schwann cells, was not released into the supernatant, but 
instead remained in the pellet (Fig.12b). 
 
 
Figure 12. (a) Brain and myelin homogenates were tested for a Golgi marker (GM130) and an ER 
marker (BiP/GRP78). (b) Myelin membrane preparation was treated with 3U of PIPLC. P: Pellet. S: 
Supernatant. 
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Expression of myelin proteins is unchanged in ∆PrPo mice 
 
Leukoencephalopathy in ∆PrPo mice exhibit features suggestive of compromised 
axon-glial adhesion, such as multiple intra-myelin splitting and axonal swelling. 
These alterations are similar to those described in mice deficient for different myelin 
proteins, such as MAG, PLP and CNP (Marcus et al 2002; Griffiths et al, 1998; 
Lappe-Siefke et al 2003). Therefore, we studied the expression levels of myelin 
proteins in ∆PrPo mice. 
We could not detect any striking differences in the protein profile of myelin 
preparations from whole brains from PrP-deficient, wild type and truncated PrP 
expressing mice, examined by silverstaining of an SDS-PAGE gel (Fig. 13, lanes 1-
4). 
 
 
Figure 13. Silverstaining of myelin preparations (1-4) and of anti-PrP immunoprecipitations (5-6) 
of various genotypes. Myelin preparations of whole brain of Prnpo/o (1), wt (2), PrP+/- (3), and ∆PrP 
(4) mice. Immunoprecipitations of myelin preparations of Prnpo/o (5), wt (6), PrP+/- (7), and ∆PrP (8) 
mice. (M) Marker.  
 
Additionally, we also investigated differences in protein levels in the different mouse 
genotypes by western blot for specific proteins such as myelin-associated 
glycoprotein (MAG), myelin basic protein (MBP) and proteolipid protein (PLP). No 
differences in protein expression between the different genotypes were revealed (data 
not shown).  
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PrPC and ∆PrP interact with a restricted but heterogeneous group of 
myelin proteins 
 
In order to identify PrPC or ∆PrP binding partners in the myelin, anti-PrP antibody 
coated paramagnetic beads were used to precipitate PrPC and ∆PrP in myelin 
preparations. Immunoprecipitations analyzed by a silverstained SDS-PAGE revealed 
that beads coated with anti-PrP antibodies incubated with myelin preparations from 
Prnpo/o mice non-specifically pulled down only a small number of proteins (Fig. 13, 
lane 5), emphasizing the specificity of the pull down. A restricted number of myelin 
proteins co-immunoprecipitated with PrP and ∆PrP (Fig. 13, lane 6-8) when compared 
to the number of proteins present in myelin inputs (Fig. 13, lane 1-4).  
Western blot analysis of the immunoprecipitations identified four proteins that co-
immunoprecipitated with PrP and ∆PrP. Two of them are proteins expressed in the 
non-compact, cytoplasm-containing myelin loops: 2’, 3’-cyclic nucleotide 3’-
phosphodiesterase (CNP), and myelin associated glycoprotein (MAG). The other two 
proteins are localized in compact myelin: myelin basic protein (MBP) and myelin-
associated/oligodendrocyte basic protein (MOBP) (Fig. 14). Whereas, proteolipid 
proteins (PLP), an integral “four-helix-span” membrane protein of the compact 
myelin, and myelin oligodendrocyte glycoprotein, a transmembrane protein of the non 
compact myelin, do not bind to PrP and ∆PrP, underlining the specificity of the 
interactions between the myelin proteins and PrPC and ∆PrP. 
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Figure 14. Pull downs with anti-PrP antibody coated beads co-immunoprecipitated CNP, MAG, 
MOBP and MBP with PrPC and ∆PrP. No interactions are seen between PrPC and ∆PrP, 
respectively, and MOG and PLP.  
 
Interactions of PrPC and ∆PrP with proteins expressed in myelin were confirmed by 
immunocytochemistry (Fig. 15) as well as co-immunoprecipitating them from spinal 
cord homogenate (data not shown). Confocal images show that CNP, MAG and MBP 
co-localize at least partially with PrP in oligodendrocytes of MBP-PrP mice. We used 
MBP-PrP mice for oligodendrocyte isolation, since oligodendrocytes from wild-type 
mice expressed PrP at undetectable levels for immunocytochemistry (Prinz et al., 
2004). Oligodendrocytes isolated from NSE-PrPo mice are deficient for PrP, as 
already shown by Western blot (Fig. 11B).  
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Figure 15. Mature murine oligodendrocytes cultured for 3 days and double immunostained for 
CNP, MAG or MBP (green) and PrP (red). MBP-PrPo mice overexpress PrP in oligodendrocytes 
(Prinz et al., 2004), whereas NSE-PrPo mice do not express PrP in oligodendrocytes.  
 
 
∆PrP is localized in lipid rafts  
 
PrPC is localized to lipid rafts (Meier et al., 2003; Naslavsky et al., 1997), where it 
may exert a physiological function by interacting with signaling molecules. If toxicity 
of ∆PrP results from interference with some PrPC–mediated signaling pathway, and 
PrPC counteracts toxicity, these two proteins may compete for the same partner in 
rafts. Moreover, ∆PrP may disrupt normal axon-glial adhesion and interaction, whose 
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integrity depend on GPI-anchored and transmembrane proteins (Bartsch, 2003; Falk et 
al., 2002; Marcus et al., 2002; Vinson et al., 2003).  
We checked the topology of ∆PrP by performing flotation assays on OptiPrep 
gradient with Triton-X-100 (TX-100) treated brain homogenates from ∆PrPo mice and 
with TX-100 treated myelin preparations from ∆PrPo mice. The mutant PrP was 
detected in low-density, detergent insoluble fractions, and displayed buoyancy similar 
to that of PrPC and flotilin (Fig. 16 and 17). These characteristics strongly suggest that 
∆PrP is indeed localized in lipid rafts from total brain as well as from myelin and 
localized to the same rafts as PrP. Therefore, cytotoxicity is not due to inappropriate 
membrane targeting of ∆PrP.  
 
 
Figure 16. OptiPrep fractions of TX-100 treated brain homogenates were analyzed for PrPC and 
∆PrP expression on immunoblots. (a) ∆PrPo, (b) ∆PrP+, (c) wild-type tissues were analyzed. Mutant 
PrPC localizes to the same rafts as PrPC. (d) Flotilin, a 48kDa marker for rafts. Fractions 1-9, 1 the 
upper most fraction, 9 the bottom fraction.  
 
The myelin proteins MAG and CNP co-localize with PrPC and ∆PrP in 
CHAPS extracted lipid rafts 
 
High cholesterol and glycosphingolipids in myelin suggests that rafts could be a major 
component of myelin and participate in the observed bi-directional signaling that 
occurs between oligodendrocytes/myelin and neurons (Sanchez et al., 1996; Vinson et 
al., 2003). Differences observed for the detergent solubility of specific myelin 
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proteins as a function of detergent-condition suggest a complex organization within 
rafts and that these detergent-specific DIGs may represent distinct biochemical, and 
possibly physiological, entities (Taylor et al., 2002a). Since PrPC and ∆PrP are found 
in the same low-density fractions and interact with the same myelin proteins, 
differences in myelin protein partition in rafts might be responsible for ∆PrP toxicity.  
Therefore, we investigated if two, MAG and CNP, of the four found interaction 
partners for PrPC and ∆PrP localize into the same rafts. We have chosen MAG and 
CNP, since similar phenotypes to the one observed in ∆PrPo mice were observed in 
mice deficient for MAG and CNP.  
We performed flotation assays on OptiPrep gradient with TX-100 and CHAPS 
extracted myelin preparation from ∆PrPo mice and compared them to the ones from 
PrPC and Prnpo/o mice. TX-100 and CHAPS were chosen, since it has been shown that 
MAG is solubilized by TX-100 (Vinson et al., 2003), but floats in lower density 
fractions when extracted with CHAPS (Taylor et al., 2002a). CNP has been shown to 
migrate within TX-100 as well as in CHAPS-insoluble fractions (Taylor et al., 2002a).  
PrPC and ∆PrP from myelin preparations treated with either TX-100 or CHAPS 
floated to the same low-density fractions of the OptiPrep gradient (Fig. 17). CNP 
displayed also a significant insolubility in both detergents and floated to the same 
low-density OptiPrep fractions as PrPC and ∆PrP. As was previously reported, MAG 
was soluble in TX-100 (Kim and Pfeiffer, 1999; Taylor et al., 2002a; Vinson et al., 
2003). However, a significant amount of MAG is insoluble in CHAPS and floated to 
the same low-density fractions as PrPC and ∆PrP. Thus, we can exclude any 
mistargeting of CNP and MAG in rafts due to ∆PrP. Both myelin proteins behave as 
described before.  
The specific co-localization in CHAPS extracted rafts might explain the partial co-
localized immunoreactivity for MAG and PrP observed in cultured oligodendrocytes 
(Fig. 15).  
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Figure 17. OptiPrep fractions of TX-100 and CHAPS-treated wild-type and ∆PrPo myelin 
preparations. Western blot analysis of PrP, ∆PrP, MAG and CNP in TX-100 and CHAPS extracted 
myelin preparations on OptiPrep gradient, 1 representing the upper most fraction, and 11 the bottom 
fraction. Unstripped membranes were reused for immunoblotting with MAG and CNP, resulting in 
increased background. 
 
Axonal p75NTR does not rescue cerebellar granule cell degeneration nor 
white matter pathology in ∆PrPo mice 
 
Oligodendrocyte-specific expression of PrPC rescues axonal degeneration in ∆PrPo 
mice, suggesting an in trans interaction of PrPC on oligodendrocytes with an axonal 
receptor. This interaction might elicit a survival signal in the axon. So far, we have 
probably investigated in cis interactions between PrPC and ∆PrP, respectively, and 
myelin proteins.  
A possible candidate for a trans interaction is the p75 neurotrophin receptor (p75NTR). 
The PrP peptide (106-126), has been shown to interact with p75NTR on CGCs (Della-
Bianca et al., 2001). In addition, PrPC and p75NTR are both present in caveolar rafts of 
the plasma membrane (Bilderback et al., 1999; Peters et al., 2003), underlining a 
possible interaction. Besides its role in neurotrophic signaling, p75NTR is implicated in 
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a diverse array of cellular responses, including apoptosis, neuronal survival, neurite 
outgrowth and myelination (Cosgaya et al., 2002; DeFreitas et al., 2001; Khursigara et 
al., 2001; Mi et al., 2004). So far, it is unknown whether ∆PrP toxicity represents a 
gain-of-function, e.g. induction of cell death, or a loss-of-function, e.g. absence of a 
survival signal.  
To investigate if the interaction between p75NTR and ∆PrP could be responsible for 
cerebellar neurodegeneration and/or axonal pathology in ∆PrPo mice, we crossed 
∆PrPo mice with p75NTR deficient mice (Lee et al., 1992) (referred to as p75o/o; ∆PrPo 
mice). The phenotype of mice lacking p75NTR (p75o/o mice) consists of a smaller size 
than their wild-type littermates and of an abnormal waddling gait.  
The ablation of p75NTR in ∆PrPo mice, however, neither delayed nor rescued the 
defects, characterized by ataxia, hind leg paralysis and wasting (Fig. 18). The ∆PrPo 
mice devoid of p75NTR died at 86 ± 8 days, whereas ∆PrPo mice expressing p75NTR 
died around 100 ± 11 days.  
 
 
Figure 18. Comparison of survival of  p75o/o; ∆PrPo mice to ∆PrPo mice. 
 
Histological analysis revealed massive cerebellar degeneration in ∆PrPo as well as in 
p75o/o; ∆PrPo mice (Fig. 19 a, b, e, f,). The faint stainings for Luxol-Nissl and 
neurofilament 200 (NF-200) indicate that important myelin and axonal degeneration, 
respectively, has occurred (Fig. 19 i, j, m, n), whereas ∆PrP+ and p75o/o mice show 
normal cerebellar architecture as well as strong staining for myelin (Luxol-Nissl) and 
axons (NF-200). 
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Figure 19. Histology of cerebella from p75o/o; ∆PrPo, ∆PrPo, ∆PrP+, and p75o/o mice. (a-d) H&E 
staining. Magnification 25x. (e-h) HE staining. Magnification 100x. (i-l) Luxol-Nissl staining. 
Arrowheads indicate the weakened staining for myelin in sick mice and arrows the normal staining for 
myelin in healthy mice. Magnification 100x. (m-p) NF-200 staining. Arrows indicate the weakened 
staining for axons in sick mice and arrows the strong staining in healthy mice. Magnification 100x.  
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DISCUSSION 
 
∆PrP induces white matter pathology 
 
Overexpression of amino terminally truncated PrPC variants collectively termed ∆PrP 
triggers not only neuronal degeneration (Shmerling et al., 1998), but also 
leukoencephalopathy. This pathology was unexpected, since PrP-related diseases are 
thought to affect primarily neurons (Chiesa et al., 1998; Hegde et al., 1998; Hegde et 
al., 1999; Rossi et al., 2001; Shmerling et al., 1998). The white matter pathology 
displayed features suggestive for compromised axon-glial adhesion similar to those 
described in mice lacking myelin-associated glycoprotein and myelin galactolipids 
(Marcus et al., 2002), as well as in mice deficient for proteolipid protein (Griffiths et 
al., 1998). In addition, we found axonal swellings similar to those of Cnp1o/o mice 
(Lappe-Siefke et al., 2003).  
Myelinopathy, rather than neuronal damage, may be a major determinant of lethality 
in Shmerling’s syndrome, since oligodendrocyte-restricted expression of PrPC 
selectively suppresses leukoencephalopathy, and restores long-term survival. Instead, 
neuron-restricted expression of PrPC, even at supraphysiological levels, does not 
prevent white matter degeneration 
 
Rescue of white matter pathology by oligodendroglial PrPC expression 
 
Oligodendrocyte-restricted expression of PrPC in ∆PrPo selectively suppresses 
leukoencephalopathy, whereas, neuron-specific expression of PrPC rescues partially 
cerebellar neurodegeneration, but not white matter disease. The presence of PrPC 
either in neurons or in oligodendrocytes restores in both cases long-term survival. 
Complete rescue, however, is only brought about by endogenous PrPC expression, 
which occurs on both neurons (Kretzschmar et al., 1986) and glia (Moser et al., 1995).  
The selective rescue of leukoencephalopathy in ∆PrPo mice by full-length PrP on 
oligodendrocytes indicates that PrPC restores in trans the axonal pathology elicited by 
mutant PrP. This suggests that PrPC transduces a cellular signal from 
oligodendrocytes to axons, analogous to other GPI anchored proteins (such as F3 and 
NCAM120) that play a role in axon-myelin interactions (Falk et al., 2002). As PrPC 
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binds in vitro to the transmembrane and GPI-linked forms of N-CAM (Schmitt-Ulms 
et al., 2001), it might contribute to the very same pathways. Alternatively, PrPC may 
instruct oligodendrocytes to release factors necessary for axonal survival (Wilkins et 
al., 2003).  
Surprisingly, neuron-specific PrPC expression did not completely rescue CGC 
degeneration. Perhaps ongoing degeneration of white matter fibers innervating the 
granule cell layer participated indirectly in granule cell degeneration, e.g. by 
deafferentiation and neuronal “dying back”. The delayed onset of myelinopathy in 
∆PrPo; NSE-PrP mice might be related to the presence of PrPC in NSE-PrP myelin, 
which, in turn, might be due to GPI cell painting (Anderson et al., 1996).  
 
PrPC present in myelin interacts with myelin proteins  
 
Similar phenotypes in mice deficient for myelin proteins such as MAG, PLP and CNP 
(Griffiths et al., 1998; Lappe-Siefke et al., 2003; Marcus et al., 2002) suggested a 
possible implication of these proteins in the myelinopathy observed in ∆PrPo mice. 
Yet, we have not found any evident changes in expression levels for any of these 
proteins.  
We could show that PrPC as well as ∆PrP are present in myelin. The full-length as 
well as the mutant prion protein seem to interact specifically with different myelin 
proteins: MAG and CNP situated in the non-compact myelin; and MBP and MOBP, 
localized to the compact myelin. Co-localization studies on mature primary 
oligodendrocytes revealed at least a partial overlapping signal for PrP and MAG, CNP 
and MBP, respectively, pointing out the specificity of the observed interactions.  
PrPC is localized to lipid rafts (Meier et al., 2003; Naslavsky et al., 1997), where it 
may exert a physiological function by interacting with signaling molecules. Lipid rafts 
have been implicated in membrane signaling (Anderson, 1993; Lisanti et al., 1994; 
Parton and Simons, 1995). If toxicity of ∆PrP results from interference with some 
PrPC–mediated signaling pathway, and PrPC counteracts toxicity, these two proteins 
may compete for the same partner on rafts. We first checked if the mutant PrP is also 
localized to lipid rafts. TX-100 treated brain homogenates and myelin preparations of 
∆PrPo mice were subjected to gradient centrifugation. ∆PrP floated to the same low-
density, detergent insoluble fractions as the full-length prion protein, underlining our 
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hypothesis and excluding that neurotoxicity of ∆PrP is due to membranal 
mistargeting. We then investigated the association of the myelin proteins MAG and 
CNP with lipid rafts. We compared TX-100 and CHAPS treated myelin preparations 
from wild-type and ∆PrPo mice. MAG has been reported to be solubilized in TX-100. 
Whereas when treated with CHAPS (a zwitterionic detergent structurally resembling 
cholesterol), this protein floats to low-density, detergent insoluble fractions. Our 
results confirmed these recent findings. PrP, ∆PrP and CNP when extracted by TX-
100 or CHAPS migrated to low-density fractions. Thus, PrPC and ∆PrP, respectively, 
and MAG and CNP shared the same rafts only, when rafts were extracted with 
CHAPS. As discussed by Taylor and colleagues (Taylor et al., 2002a), differentially 
extracted rafts may represent biochemically, eventually physiologically relevant, 
entities.  
 
The interaction between PrPC or ∆PrP and the non-compact myelin 
proteins MAG and CNP 
 
Myelin-associated glycoprotein (MAG) is a minor, but important constituent of 
myelin, comprising 1% of all myelin proteins in the CNS (Trapp, 1990). It is an 
integral membrane glycoprotein (Poltorak et al., 1987; Yin et al., 1998) and member 
of the immunoglobulin gene superfamily (Salzer et al., 1987). When compact myelin 
has formed, expression of MAG becomes restricted to the periaxonal region of the 
myelinating cell (Sternberger et al., 1979), which is consistent with its known function 
in glial-neuronal interactions (Domeniconi et al., 2002; Franzen et al., 2001; Vyas et 
al., 2002). Mag knockout mice produce relatively normal myelin, but develop late-
onset degeneration of axons and myelin (Fruttiger et al., 1995; Yin et al., 1998).  
The extracellular domain of MAG predisposes the molecule for interactions with 
ligands and receptors (Schachner and Bartsch, 2000). Moreover, it has been suggested 
that the extent of MAG-mediated interactions in trans (i.e. between two apposing cell 
membranes) is regulated in cis (i.e. within the same cell membrane) by sialic acid 
containing constituents (Tropak and Roder, 1997). We have shown that PrPC 
expressed on oligodendrocytes suppresses axonal degeneration, indicating that PrPC 
rescues the pathology by an interaction in trans with an axonal molecule. 
Alternatively, our co-immunoprecipitation studies in myelin suggest cis interactions 
with myelin proteins.   
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Since the prion protein contains two N-linked glycosylation sites that carry sialic 
acids, a cis interaction between MAG and PrP becomes likely. This cis interaction 
might enhance the in trans interaction of MAG with an axonal receptor, giving rise to 
survival signal for the axon. MAG has been shown to interact with Nogo66 receptor 
on neurons (Domeniconi et al., 2002) that may initiate a bi-directional signaling 
system that results in inhibition of neurite outgrowth postnatally and maintenance of 
myelin integrity. The inhibition of neurite outgrowth is probably mediated via 
activation of Rho A kinase, whereas the maintenance of myelin integrity is probably 
regulated via the activation of Fyn kinase (Vinson et al., 2001; Vyas et al., 2002; 
Wong et al., 2002; Yamashita et al., 2002). 
Crosslinking of MAG (Umemori et al., 2002) and PrP (Mouillet-Richard et al., 2000) 
with specific antibodies have been shown to result in activation of Fyn kinase, 
suggesting a common signaling pathway. Because PrPC is GPI-linked to the neuronal 
surface, its lack of cytoplasmic domain suggests the participation of an interacting 
transmembrane receptor subunit that activates Fyn. Activation of Fyn might elicite a 
signaling pathway that instructs oligodendrocytes to maintain myelin integrity and 
release trophic factors to support axons. Given the association between MAG and PrP, 
it is tempting to speculate that such a signaling cascade might involve MAG.  
The N-terminally truncated PrP still interacts with MAG, but the missing flexible N-
terminal part might hinder a functional interaction leading to an abnormal signaling – 
either suppressed or enhanced – leading to the phenotype observed in ∆PrPo mice 
(Fig. 4). 
2’, 3’-Cyclic nucleotide 3’phosphodiesterase (CNP) exists in two isoforms of 46 and 
48 kDa. It accounts for approximately 4% of all CNS myelin protein and is distributed 
throughout the cell soma (Nishizawa et al., 1985) and in non-compacted regions of 
myelin (Braun et al., 1988; Trapp et al., 1988). Both proteins are acylated (Braun et 
al., 1991; De Angelis and Braun, 1994), which explains their efficient association 
with the cytoplasmic cellular membrane. It is, therefore, not evident how the 
interaction between full-length PrP or the mutant PrP, both GPI-anchored proteins 
situated at the outer surface of the membrane, and CNP, situated at the inner leaflet of 
the membrane, occurs. Perhaps, CNP binds indirectly via a third molecule, e.g. MAG, 
to PrP. In this complex, CNP might act as a downstream effector.  
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The function of CNP does not shed light on the importance and significance of the 
interaction between PrPC and CNP. It has been shown to hydrolyze 2’3’-cyclic 
nucleotides into their 2’-derivatives. However, because 2’3’-cyclic nucleotides have 
not been found in the brain, the function of CNP remains obscure. CNP influences 
cell morphology (De Angelis and Braun, 1994) and is thought to be a regulator of 
events leading to myelination (Braun et al., 1991), so the finding that Cnp1 knockout 
mice developed myelin that was biochemically, ultrastructurally, and morphologically 
normal was unexpected (Lappe-Siefke et al., 2003). However, at about 4 months of 
age, the mice developed motor deficits that progressed with age. Histological analysis 
revealed late-onset axonal pathology characterized by abnormal axonal swellings and 
degeneration of many axons, clearly not related to dys- or demyelination (Lappe-
Siefke et al., 2003). In these mice, axonal degeneration is not caused by abnormal 
myelination but constitutes a primary phenotype of CNP deficient-mice.  
 
The interaction between PrPC or ∆PrP and the compact myelin proteins 
MBP and MOBP 
 
Myelin basic protein is one of the major proteins of the CNS myelin and constitutes as 
much as 30% of myelin proteins. In fact, it is a family of proteins, as there are many 
isoforms of different molecular masses. The molecular masses of the major forms are 
21.5, 18.5, 17 and 14 kDa in the mouse. In the adult, the predominant isoforms are 
18.5 and 14 kDa, constituting 95% of the MBPs. MBP is bound to the cytosolic side 
of the oligodendrocyte membrane, primarily through electrostatic interaction with 
acidic lipids. Direct evidence that MBPs play a major role in myelin compaction in 
the CNS was provided from studies of the shiverer mutant mouse, which presents a 
large deletion of MBP gene (Roach et al., 1985) and in which the major dense line is 
absent from myelin (Privat et al., 1979).  
The interactions seen between MBP and PrPC or ∆PrP seem to be specific. However, 
these interactions lack evidence about how the interaction takes place, since PrP and 
MBP are placed opposite each other on the membrane. As MBP has been shown to 
bind to CNP (Harauz et al., 2004), it might form a complex with PrP, MAG, and 
CNP, in which MBP takes over the role in signal transduction. Indeed, it has been 
proposed that MBP is involved in signal transduction (Dyer, 2002; Dyer et al., 1994). 
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Since ∆PrPo mice do not show any abnormalities in myelin periodicity and spacing, 
PrPC seems not to be involved in compaction of myelin.  
Myelin-associated oligodendrocyte basic protein (MOBP) is, like MBP, a highly basic 
and positively charged protein (Yamamoto et al., 1994). Six splice variants have been 
identified which are predicted to encode five different protein isoforms of MOBP 
(Holz et al., 1996; Yamamoto et al., 1994). Though all isoforms so far identified have 
amine acid residues 1-68 in common, they differ in the length and polarity of their 
respective C-terminal regions (Holz et al., 1996; Montague et al., 1997) that contains 
a cluster of positively charged residues. These positively charged amino acids are 
considered to interact with phospholipids in the inner surface of the plasma 
membrane, and are concentrated where the cytoplasmic faces of the myelin sheath are 
in apposition, leading to the formation of myelin dense lines (MDLs) together with 
MBP. Since MOBPs are located in the MDL of myelin, they could play a similar role 
to MBP in myelin compaction (Holz and Schwab, 1997). However, MOBP-deficient 
mice exhibit no obvious phenotype (Yamamoto et al., 1999; Yool et al., 2002), 
suggesting that it is not essential for forming compact myelin. Thus, its physiologic 
function remains unclear. Although the association between PrPC and ∆PrP with 
MOBP seemed to be specific, its biological relevance remains enigmatic.  
During purification of the PK-resistant core of PrPSc (PrP27-30), several molecules have 
been identified that co-purified with PrP27-30 and prion infectivity (Stahl et al., 1993). 
It is unknown whether these molecules simply represent contaminants with physical 
properties similar to PrP27-30, or whether they participate as components of the prion. 
These molecules included peptides with sequences DGPRLSK and REIVDRK. The 
source of these peptides was not known at that time, but performing a database search, 
we retrieved one protein containing both peptide sequences, MOBP. We found that 
MOBP is resistant to PK (data not shown), explaining partially its ability to co-purify 
with PrP27-30. If MOBP plays a role in prion disease propagation or transport is 
currently under investigation.   
 
Trans-interaction of PrP with an axonal protein 
The interactions between PrPC or ∆PrP and the myelin proteins most probably occur 
in cis. However, the rescue of myelinopathy in ∆PrPo mice by oligodendrocytes-
 52
 
 
 
specific expression of PrPC suggests an interaction in trans with a receptor or a ligand 
on the axon.  
PrP has been shown to act as a trans-interacting partner for neurons and to promote 
neuronal survival and neurite outgrowth (Chen et al., 2003; Kuwahara et al., 1999). 
Recently, the p75 low affinity NGF receptor (p75NTR) has been reported to bind a 
prion protein fragment, PrP (106-126). In addition, PrPC and p75NTR are both present 
in caveolar rafts of the plasma membrane (Bilderback et al., 1999; Peters et al., 2003), 
underlining a possible interaction. p75NTR is implicated, besides its role in 
neurotrophic signaling, in a diverse array of cellular responses, including apoptosis, 
neuronal survival, neurite outgrowth and myelination (Cosgaya et al., 2002; DeFreitas 
et al., 2001; Frade et al., 1996; Khursigara et al., 2001; Mi et al., 2004). Although it 
may seem curious that p75NTR signaling causes both cell death and cell survival, this 
is the case for other members of the TNF receptor superfamily (Nagata, 1997). p75NTR 
has been shown to interact with Nogo-66 receptor and mediate growth cone and 
neurite outgrowth inhibition, the signaling of which are elicited by the binding of 
MAG, Nogo-A and OMgp to the Nogo-66 receptor (Wang et al., 2002).  
Based on these findings, we have speculated that an interaction between ∆PrP and 
p75NTR could elicit a signal leading to cell death and axonal pathology. Therefore, we 
bred p75NTR deficient mice with ∆PrPo mice in order to see if axonal pathology and 
cerebellar granule cell degeneration are rescued by the ablation of p75NTR.  
However, disease onset and lifespan of p75o/o; ∆PrPo mice did not differ from ∆PrPo 
mice. Histological analysis revealed a thinned cerebellar granule cell layer due to 
neuronal degeneration and coarse vacuolation in white matter. Moreover, Luxol-Nissl 
staining was significantly weakened in the p75o/o; ∆PrPo mice cerebellum and spinal 
cord of p75o/o; ∆PrPo mice compared to wild-type mice, indicating myelin 
degeneration. Axon degeneration also occurred, as evidence by a faint NF-200 
staining. p75 receptor deficient mice, that we have used in our studies, still expressed 
a shorter splice variant that is unable to bind neurotrophins (Lee et al., 1992). 
Incomplete ablation leads to a phenotype in the peripheral nervous system with 
hypomyelination and a decrease in the number of axons (Cosgaya et al., 2002). 
Phenotypically, the mice are smaller than their littermates and show a waddling gait. 
In contrast, in ∆PrPo mice, we have not observed any pathology in the peripheral 
nervous system. In the p75o/o; ∆PrPo mice, the sciatic nerve is macroscopically thinner 
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probably due to the described decrease in number of axons and hypomyelination (Lee 
et al., 1992; von Schack et al., 2001). However, this additional pathology has no 
influence on the course of the disease. Complete ablation of all p75NTR isoforms 
produced a larger decrease in the number of neurons and Schwann cells present in the 
sciatic nerve compared with the traditional p75NTRo/o mice (von Schack et al., 2001). 
In addition, the absence of both isoforms leads to partial perinatal lethality and defects 
in the vascular systems. This suggests an additional neurotrophin-independent role for 
this receptor and/or redundant function of the isoforms. The incomplete ablation 
might be insufficient to rescue ∆PrP-induced pathology. However, more likely, the 
observed in vitro interaction between PrP and p75NTR is not relevant in vivo.    
 
PrPC seems to play a role in myelin physiology 
 
The white matter pathology in ∆PrPo mice displayed features suggestive of 
compromised axon-glial adhesion, such as intra-myelin splitting and axonal swellings. 
These changes are similar to those described in mice lacking MAG and myelin 
galactoplipids (Marcus et al., 2002), and PLP (Griffiths et al., 1998). In addition, we 
found axonal swellings similar to those of Cnp1o/o mice (Lappe-Siefke et al., 2003). 
These data from myelin protein gene null mice highlight the dual role of the 
oligodendrocytes: first, in formation of the myelin sheath and, second, in supporting 
the underlying axon. The axon-myelin complex may be a primary target of ∆PrP. The 
finding, that full-length prion protein represses the defects induced by the mutant 
prion protein, suggests that PrPC plays a role in myelin physiology, in 
oligodendroglial-mediated axonal support and axon-myelin interaction. The 
interaction of PrPC with a variety of myelin proteins underscores this possible role. A 
delay in initiation of myelination was excluded as a cause for the observed white 
matter disease in ∆PrPo mice. Abnormal myelin structure was also ruled out as a 
reason for myelin and axonal degeneration, further supporting the importance of PrPC 
in axon-glial interaction. The late onset of axonal degeneration seen in ∆PrPo mice 
indicate that axonal requirements change over time and that the factors required for 
the development and maintenance of the myelinated axon are different or deficits in 
myelin-axonal signaling accumulate until a threshold is reached whereupon axonal 
degeneration begins. A possible role for PrPC in myelin maintenance is further 
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supported by demyelination of the peripheral nervous system in the PrP null mouse, 
that provokes no phenotype but is corrected by PrP expression (Nishida et al., 1999).  
However, the biological and physiological relevance of the interactions between PrPC, 
or ∆PrP, and myelin proteins remain to be proven. ∆PrP might sequester myelin 
proteins, that seem to be necessary for axonal support, or ∆PrP might interfere with 
the physiological function of one of the identified myelin proteins, consisting of signal 
transduction or axon-glial interaction. How myelin proteins act on the health of an 
axon remains unclear. Recently, Menon and colleagues (Menon et al., 2003) have 
reported that high-affinity protein-protein interactions occur between myelin and the 
axolemma, which may be potential sites for bi-directional signaling. Or, myelin 
proteins exert a trophic action on the axon, directly or indirectly mediated by 
downstream factors.  
 
Ongoing studies to reveal the biological relevance of the interactions 
between PrP or ∆PrP and myelin proteins  
 
In vivo and in vitro studies support a trophic role for oligodendrocytes on nearby 
neurons. Conversely, expression of growth factors by oligodendrocytes is influenced 
by neural signals.    
In vivo maturation of axons, as indicated by neurofilament development (Sanchez et 
al., 1996) or the clustering of sodium channels (Kaplan et al., 1997), is correlated with 
oligodendrocyte ensheatment. Additionally, myelin proteins such as PLP and CNP 
have been implicated in axonal support (Griffiths et al., 1998; Lappe-Siefke et al., 
2003).  
Identified trophic factors that may be responsible for trophic support include: BDNF, 
NT-3 (Dai et al., 1997) and IGF-1 (Wilkins et al., 2001). These factors have been 
shown to be produced by oligodendrocytes. In addition to the expression of 
neurotrophins and IGF-1, recent literature suggests that oligodendrocytes produce 
neuregulins and GDNFs, as well as transforming growth factor-βs, and fibroblast 
growth factor-9 (Du and Dreyfus, 2002).  
Interaction between PrP and myelin proteins might lead to activation of a signaling 
pathway that instructs oligodendrocytes to secret such trophic factors. In the case of 
∆PrP, this signal might be missing and the absence of the trophic factor eventually 
leads to axonal pathology.  
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To test for oligodendrocytic dysfunction due to ∆PrP expression, we are currently 
establishing an in vitro model.  Primary oligodendrocytes of ∆PrPo mice are cultured 
in serum-free medium. This medium is then transferred onto neurons, e.g. primary 
cerebellar granule cells or dorsal root ganglia, to test for its ability to induce axonal 
degeneration (Wilkins et al., 2003). Another approach using co-cultures of DRGs and 
oligodendrocytes isolated from ∆PrP and wild-type mice might also be used to check 
for oligodendrocytic dysfunction and enhanced axonal degeneration.  
To test the relevance of the association between PrPs and myelin proteins in vivo, we 
are breeding the different myelin protein deficient mice with Prnpo/o and ∆PrPo mice. 
If PrPC has a role in myelin maintenance or axonal support, we might see an enhanced 
phenotype in the double knockout mice. Often the ablation of one myelin protein does 
not lead to a characteristic phenotype, however, the deletion of two myelin proteins 
often induces an enhanced phenotype (Biffiger et al., 2000; Marcus et al., 2002; 
Uschkureit et al., 2000). If one of the myelin proteins is important in mediating an 
aberrant signaling due to the interaction with ∆PrPo, we might even rescue the 
pathology in ∆PrPo mice. Furthermore, we inoculated small groups of Mago/o (Montag 
et al., 1994) and Mobpo/o (Yool et al., 2002) mice intracerebrally or intranervally with 
high and low dose of scrapie prion (Rocky Mountain Laboratory (RML) strain, 
passage 5), in order to see if one of the myelin proteins could be important for the 
transport or replication of the infectious prion protein. Cnp deficient mice (Lappe-
Siefke et al., 2003) as well as Mbp deficient mice (Chernoff, 1981) are not suitable for 
inoculation, since they have a limited lifespan of 210-330 and 90-150 days, 
respectively. The mechanism, which is involved in prion spread to and within the 
CNS, is not yet clear. There are data that support the hypothesis of axonal prion 
transport (Brandner et al., 1996b; Fraser, 1982). Other findings, however, suggest 
nonaxonal transport mechanisms that result in periaxonal deposition of PrPSc (Glatzel 
and Aguzzi, 2000; Hainfellner and Budka, 1999). One might hypothesize a “domino” 
mechanism, by which incoming PrPSc converts resident PrPC on the axolemmal or 
myelin surface, thereby spatially propagating the infection (Aguzzi and Weissmann, 
1997). Mice that express PrPC selectively in oligodendrocytes have been shown to be 
resistant to prion infection, ruling out that oligodendrocytes replicate and propagate 
PrPSc. Therefore, PrPC expressed on myelin surface can be excluded to be important 
for prion spread. However, one could speculate that other proteins on the myelin 
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surface help to convert and propagate prions. Since myelin proteins have been 
implicated as regulators of axonal transport (de Waegh and Brady, 1990; Kirkpatrick 
et al., 2001), myelin proteins might also be implicated in prion spread.  
 
Conclusion 
 
Our data are clearly consistent with a function of PrPC in myelin physiology and 
axon-glial interaction. The interaction with myelin proteins in this context is plausible. 
However, further experiments are necessary to sustain their biological relevance. In 
addition, we cannot rule out the importance of a high-affinity interaction of PrPC with 
an axonal protein complex that gives rise to a survival signal. ∆PrP seems to abrogate 
this function of myelin maintenance and axon-glial interaction and therefore is a 
suitable model to test for the importance of the interaction in vivo and in vitro.   
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An in vitro model to dissect mechanisms leading to cell death 
induced by amino-terminally truncated prion protein and 
Doppel 
 
RESULTS 
Lentiviral constructs 
 
The cDNA of Prnp, ∆Prnp and Prnd were fused to an internal ribosomal entry site 
(IRES) controlling the expression of green fluorescent protein (GFP) (e.g. Dpl-IRES-
GFP). From these constructs a bicistronic mRNA encoding the cDNA of interest and 
GFP is transcribed that provides GFP levels as a surrogate marker for cDNA 
expression and allows for quantification of transduced cells by fluorescence-activated 
flow cytometry (FACS). These constructs were then cloned into a 3rd generation 
lentiviral transfer vector, pCCLsin.PPT.CMV.eGFP.Wpre (Follenzi and Naldini, 
2002) (Fig. 20). The envelope construct, pMD.G, expressing the surface glycoprotein 
VSV.G, and the packaging construct, pCMV∆R8.91, encoding the proteins and 
enzymes of the vector core, were from the 2nd generation of lentiviral vectors (Fig. 
20). 
 
 
Figure 20. The three-plasmid vector system used to generate the different lentiviral vectors. SA 
and SD Splice acceptor and donor sites, ψ the packaging sequence, GA 5’ portion of gag gene with 
truncated reading frame including extended packaging signal, RRE Rev Response Element, PolyA 
polyadenylation site, cPPT central polypurine tract, Wpre posttranscriptional regulatory element from 
the genome of the woodchuck hepatitis virus, VSV.G glycoprotein of vesicular stomatitis virus, which 
gives the vector a wide host range (adapted from Follenzi and Naldini (Follenzi and Naldini, 2002)). 
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Assaying transducing activity  
 
To verify transducing activity of vector stocks, we performed end-point titration on 
T293 cells and analyzed them subsequently by FACS. Figure 21 illustrates FACS 
analysis of T293 cells that were transduced with the constructs of CMV.eGFP and of 
CMV.Dpl.IRES.eGFP. The titers of the constructs containing the different cDNAs 
were always lower than the titers of the eGFP construct. The lowest dilution of the 
eGPF lentivirus (independent productions) yielded at least 75% of eGFP positive 
cells, whereas the virus of PrP, ∆PrP and Dpl virus produced approximately 25% of 
eGFP positive cells. Nevertheless, the titers for PrP, ∆PrP and Dpl virus were still in 
the expected range of 108-109 transducing units (TU)/ml.  
 
 
Figure 21. Titration of eGFP and Dpl lentivirus on T293 cells. (a) T293 cells transduced with eGFP 
lentiviral construct. GFP 1 - GFP 6: dilution from 10-1 - 10-6. (b) T293 cells transduced with Dpl 
lentiviral construct.  Dpl 1 - Dpl 6: dilution from 10-1 - 10-6. 
 
 
In addition, we compared IRES.eGFP expression to PrP expression by labeling the 
cells with an anti-PrP antibody (6H4) and a Cy3–conjugated secondary antibody. We 
gated for endogenous PrP expressed by T293 cells in non-transduced cells and 
compared them to T293 cells transduced with different concentrations of lentiviral 
vector expressing the full-length prion protein (Fig. 22). Based on the FACS data, we 
can conclude that eGFP expression and PrP expression coincide. Therefore, eGFP 
based end-point titration was used for titer calculation.  
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Figure 22. Comparison between PrP and eGFP expression in T293 cells. (a) Endogenous PrP 
expression in untransduced T293 cells. Expression of PrP and eGFP in T293 cells transduced with 
three different dilutions of PrP lentivirus: (b) 10-1 (c) 10-2 (d) 10-3.  FL4-H: signal for cy3 antibody. 
FL1-H: signal for eGFP.  
 
Expression of the different proteins from lentiviral transduced murine 
CGCs 
 
CGCs were transduced with various amounts of the different lentiviral vector stocks. 
The cells showed a visually detectable GFP expression 2 days after transduction. 
After three days, the cells were lysed and the expression levels of each vector were 
evaluated on Western blots (Fig. 23a). All three proteins were expressed at reasonable 
levels and showed an expression - lentivirus dose correlation. Figure 23b illustrates 
the expression of ∆PrP over time. The protein can be detected as early as 33h after 
transduction of the primary neurons.  
 
 
Figure 23. (a) Western blot analysis of protein expression in Prnpo/o CGCs transduced with 
different lentiviral constructs. Different concentrations of PrP, ∆PrP and Dpl virus were used. (b) 
Time course of protein expression in Prnpo/o CGCs. Faint expression can be seen 33h after 
transduction. MW of ∆PrP is 25kDa. C untransduced Prnpo/o CGCs. M Marker.  
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By immunocytochemistry, we evaluated if the proteins are expressed and compared 
the expression pattern to the one of PrP in wild-type CGCs (Fig. 24). On confocal 
microscopy, the expression of proteins of lentiviral-transferred cDNA for PrP, ∆PrP 
and Dpl resembled the expression pattern of PrP from CGCs isolated from wild-type 
mice. GFP expression, due to the IRES.GFP fused to each cDNA, of the transduced 
cells co-localized with the expression of PrP, ∆PrP and Dpl. 
 
 
Figure 24. Immunostainings of wt CGCs and lentiviral transduced Prnpo/o CGCs. (a) CGCs from 
wild-type mouse. CGCs from Prnpo/o mouse transduced with lentiviral vector expressing PrP (b), ∆PrP 
(c) and Dpl (d). The labeling in (a), (b), and (c) was performed with monoclonal anti-PrP antibody 
(6H4) detected by 2nd antibody labeled with Alexa546. In (d) polyclonal anti-Dpl antibody detected by 
2nd antibody labeled with Alexa546 was used. The overlapping yellow staining is indicative of PrP and 
eGFP co-localization. Magnification: 630x. 
 
Transduction efficiency  
 
We evaluated then the transduction efficiency of CGCs of the different lentiviral 
stocks that were independently prepared. 320’000 CGCs were seeded prior to 
transduction with either 2µl or 10µl of each viral stock. High transduction efficiency 
was obtained in the case of the CMV.eGFP virus: 40% for 2µl and 57% for 10µl (Fig. 
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25). In the case of PrP, ∆PrP and Dpl, the eGFP positive cells were between 4 and 
10%, when the low concentration of virus was used. The higher concentration of virus 
led to 11-15% of eGFP positive cells.  
 
 
Figure 25. Efficiency of lentiviral transduction of CGCs. (a) 2µl of viral stock corresponding to 
2*104 TUs and (b) 10µl of viral stock corresponding to 105  TUs were used to transduce CGCs isolated 
from Prnpo/o mice. 
 
Absence of cell death in CGCs transduced with lentivirus expressing 
∆PrP and Dpl 
 
Primary cultures of CGCs from ∆PrPo mice did not show any sign of cell death after 
three weeks in culture (personal communication by Marcel Leist), which represents 
the upper limit of viability in general of CGCs in culture (Ishitani et al., 1996). 
Therefore, we thought to establish an in vitro model using CGCs and lentivirus to 
study the mechanism of ∆PrP and Dpl induced cell death observed in mice expressing 
∆PrP and Dpl. CMV driven expression might lead to higher expression levels of the 
proteins and accelerate cerebellar granule cell death in vitro. 
The viability of CGCs was evaluated 8 days after transduction with the three different 
lentiviral constructs PrP, ∆PrP and Dpl either by PI staining or by Tunnel staining. 
None revealed increased cell death in cells transduced with ∆PrP and Dpl lentiviral 
vectors compared to PrP transduced cells (Fig. 26). However, the lentivirus itself 
seems to have some neurotoxic effects as suggested by the significant p-values 
(p<0.005) when untransduced and eGFP transduced cells were compared. Recently, 
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eGFP expression has been shown to induce apoptosis in non- and neuronal cells 
(Detrait et al., 2002; Liu et al., 1999). But we can exclude this as a reason for the 
observed increased cell death in our cultures, since we did not observe a reduction of 
eGFP positive cells overtime. Additionally, there is also a statistically significant 
toxicity induced by the PrP lentivirus, and probably also by ∆PrP and Dpl, when 
compared to the eGFP lentivirus. Either overexpression of PrP is unexpectedly toxic 
and as toxic as ∆PrP and Dpl to CGCs, or the lentiviral stocks contain some 
contaminants, being toxic for CGCs. However, the first reason seems unlikely, as 
tga20 mice that overexpress PrP do not show any cerebellar neurodegeneration 
(Fischer et al., 1996). To exclude the second reason, bulk assays should be performed 
to verify that excess non-infectious particles and other contaminants do not interfere 
with vector performance (De Palma and Naldini, 2002).  
In this experiment, we simply counted the PI positive cells without taking into 
account the eGFP positive cells, i.e. the transduced cells. However, the fields that 
were counted did not show any cells that were double-labeled for eGFP and PI that 
would indicate specific cell death in transduced cells. To analyze cell death induced 
by the expression of ∆PrP and Dpl in more detail, FACS analysis should be 
performed on eGFP positive CGCs co-stained with PI or Annexin-V as well as 
cytotoxicity assays and/or viability assays.   
 
 
Figure 26. No cell death is induced in CGCs by lentiviral construct expressing ∆PrP and Dpl 
compared to CGCs transduced with PrP lentivirus. (a) 2µl of viral stock corresponding to 2*104 TU 
and (b) 10µl of viral stock corresponding to 105  TU were used to transduce CGCs isolated from Prnpo/o 
mice. Cell death was assessed by PI staining of CGCs 8 days after lentiviral transduction. Significant 
differences were determined using the t test and are indicated by * with p<0.005, by ** with p<0.05 (a) 
and p< 0.001 (b). 
 63
 
 
 
DISCUSSION 
 
Overexpression of Dpl in Prnpo/o mice, due to enhanced intergenic splicing when the 
splice acceptor site is deleted on Prnp exon 3, leads to progressive ataxia and 
cerebellar cell degeneration (Moore et al., 2001; Moore et al., 1999; Rossi et al., 2001; 
Sakaguchi et al., 1996). A similar phenotype was described in mice expressing the 
globular domain of PrP lacking the flexible N-terminus (∆PrP) (Shmerling et al., 
1998). In both cases, reintroduction of a PrP gene abrogated the cerebellar syndrome 
(Flechsig et al., 2003; Nishida et al., 1999; Rossi et al., 2001; Shmerling et al., 1998). 
Because the overall structure of Dpl is remarkably similar to that of ∆PrP, and 
because full length PrP antagonized both Dpl and ∆PrP induced neuronal cell death, 
the mechanism of pathogenesis might be the same in both ataxic syndromes (Moore et 
al., 1999; Weissmann and Aguzzi, 1999). In order to study this common molecular 
mechanism(s), we established an in vitro model using primary cerebellar granule 
neurons isolated from Prnpo/o mice and lentiviral vectors to transfer the genes of 
interest (Prnd, Prnp, ∆Prnp) to the cells. Primary cerebellar granule neurons are a 
well characterized model system for investigating neuronal death (Galli et al., 1995). 
Since they are non-dividing cells, lentiviral vectors are an adequate tool for gene 
transfer into neurons.  
The cDNA of PrP, Dpl and ∆PrP were efficiently transferred to the Prnpo/o CGCs by 
the lentiviral vectors and protein expression was observed at 33h post-transduction. 
The expression patterns of the different proteins, expressed in CGCs of mice deficient 
for PrP, were comparable to the one of wild-type neurons. The number of eGFP 
positive CGCs between the different lentiviral stocks varied significantly, suggesting 
that the transduction efficiency is not yet optimally assayed. In addition to the end-
point titration a bulk assay should be performed, i.e. by measuring the maximal 
frequency of transduction that is obtained when high vector input is used. Moreover, 
bulk assays verify that excess of non-infectious particles and other contaminants do 
not interfere with vector performance (De Palma and Naldini, 2002). To increase 
transduction efficiency, higher TU/ml and fewer medium will be used, so that the 
possibility that vectors and cells encounter each other is enhanced. Other strategies to 
increase the chance of vector particles to come into contact with the target cells, such 
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as prolonged centrifugation of vector together with the cells (spinoculation) 
(O'Doherty et al., 2000) will also be employed.  
Surprisingly, we did not observe cell death induced by the expression of ∆PrP and 
Dpl when compared to PrP transduced CGCs.  
This could be due to insufficient expression of the proteins to induce cell death. 
Cerebellar cell degeneration in ∆PrP and Dpl expressing mice has clearly been shown 
to be dose-dependent (Anderson et al., 2004; Rossi et al., 2001). In cells transduced 
with lentiviral vectors, the average expression level depends on the copy number of 
integrated vectors (De Palma and Naldini, 2002). Since we have used low 
concentrations of virus, only a few cells might have integrated multiple copies of the 
transgene that could lead to expression levels inducing cell death.  
In addition, the absence of cell death in ∆PrP and Dpl transduced CGCs suggests that 
the mechanisms leading to cell death might be dependent on other cell types, e.g. 
Purkinje cells. It has been shown that Purkinje neurons provide critical trophic support 
to cerebellar granule cells (Linseman et al., 2002). Moreover, degeneration and loss of 
Purkinje neurons in Lurcher cerebellum (point mutation in the δ2 glutamate receptor 
(GluRδ2)) is followed by secondary death of cerebellar granule neurons and inferior 
olivary neurons attributable to loss of trophic support normally provided by their 
afferent target Purkinje neurons (Wetts and Herrup, 1982). However, Dpl expressed in 
Purkinje cells leads to Purkinje cell death in absence of secondary cerebellar granule 
cell death (Moore et al., 1999). Moreover, ubiquitous expression of Dpl in the brain of 
Prnpo/o mice causes severe ataxia associated with loss of both granule and Purkinje 
cells (Moore et al., 2001). In addition, overexpression of N-terminally truncated PrP 
targeted specifically to Purkinje cells of ZrchI PrP knock out mice (under the control 
of the Purkinje cell-specific L7 promoter) resulted in the same phenotype observed in 
the Nagasaki-type PrP knock out mice, namely ataxia and Purkinje cell degeneration 
(Flechsig et al., 2003). Moreover, no secondary granule cell death was reported. 
However, Prnpo/o mice that express Dpl under the transcriptional control of L7 
promoter evidenced initial Purkinje cell death followed by granule cell death, likely as 
a consequence of the absence of critical inputs from Purkinje cells rather than of a 
direct effect of the transgene (Anderson et al., 2004). These results suggest that cell 
specific expression of Dpl and ∆PrP induces pathways that lead to death of the 
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particular cell type. However, the presence of other cell types, such as microglia and 
astrocytes, might be important for inducing cell death. 
Another possibility is that the conditions in the culture model do not simulate the 
conditions leading to cell death in ∆PrP and Dpl overexpressing mice. First, primary 
neurons are prepared from the developing nervous system. Thus, CGCs lack the 
natural environment when they differentiate in vitro that might lead to absence of 
protein expression occurring in vivo. Second, in ∆PrPo mice cerebellar granule cell 
apoptosis starts to be evident at the age of three weeks (Shmerling et al., 1998). 
However under typical culture conditions, cerebellar granule cells die after about 17 
days in vitro (Ishitani et al., 1996).  
In addition, CGCs require activity-dependent signals (membrane depolarization) and 
serum for their survival in vitro (D'Mello et al., 1993; Galli et al., 1995; Miller et al., 
1997). After removal of serum and lowering of extracellular potassium form 25 to 
5mM, CGCs undergo rapid apoptotic cell death characterized by caspase activation 
and nuclear condensation and fragmentation. Therefore, triggering cell death in 
lentiviral vector-transduced cultures by withdrawal of serum and potassium might 
reveal a difference in survival between PrP, ∆PrP and Dpl transduced neurons. 
Introduction of one transgene of full-length PrP in the Dpl or ∆PrP overexpressing 
mice protects the neurons from dying, suggesting a neuroprotective role of PrPC. The 
neuroprotective function of PrP seems to require the octapeptide repeats, because the 
deletion of amino acids 23-88 abrogates the ability of PrP (hamster/mouse chimeric 
PrP) to protect against Dpl (Atarashi et al., 2003). In contrast, mice expressing ∆PrP 
crossed with mice expressing PrP lacking the octarepeats (PrP∆32-93) completely 
suppress the neurological syndromes. However, PrP∆32-106 could no longer abolish 
the defect (Flechsig and Weissmann, 2004). It has also been shown that the absence of 
PrP in vitro or in vivo contributes to an increased susceptibility to oxidative stress 
(Brown and Besinger, 1998; Brown et al., 2002) or apoptosis-inducing insults (Chen 
et al., 2003; Mouillet-Richard et al., 2000). These data suggest that PrP exerts a 
neuroprotective function (for review (Roucou et al., 2004)). In contrast, ∆PrP and Dpl 
has been shown to induce neurodegeneration in vivo as well as in vitro (Anderson et 
al., 2004; Cui et al., 2003; Daniels et al., 2001; Flechsig et al., 2003; Moore et al., 
2001; Rossi et al., 2001; Shmerling et al., 1998) 
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In order to identify the mechanism(s) responsible for cell death in the cerebellum in 
mice expressing Dpl and ∆PrP, we intend to perform microarrays on CGCs 
transduced with the various lentiviral vectors. Cell death might not be evident in these 
cultures due to the limited lifespan of CGCs in culture, but subtle changes at the 
molecular level might already be detectable in Dpl and ∆PrP compared to PrP 
transduced cerebellar granule cells.  
Moreover, in order to model more adequately an in vivo situation, we plan to use 
cerebellar slices and to transduce the cells with the different lentiviral vectors. This 
model might enable us to evaluate the importance of the presence of other cell types 
for the induction of cerebellar granule cell death.  
We might also test different conditions, e.g. lowering potassium levels and serum 
concentration, in order to study the susceptibility of CGCs to cell death, that are 
transduced with the various lentivirus. Proteasome inhibitors added to cultures might 
also imbalance the cell culture system toward cell death, when cells are transduced 
with Dpl and ∆PrP but not when transduced with PrP.  
Recently, it has been proposed that mutant prion pathology was derived from altered 
processing of misfolded prion and retrograde transport to the cytosol (Ma and 
Lindquist, 2001; Ma et al., 2002). Inhibition of proteasome function in neuronal cell 
lines highly expressing PrPC as well as expression of a PrP mutant targeted to and 
accumulating in the cytosol (cyPrP), induced neuronal death in vitro and 
neurodegeneration in transgenic mice (Ma et al., 2002). Does ∆PrP induce cerebellar 
granule cell death by a similar mechanism? However, several observations argue 
against a similar mechanism of neurotoxicity for ∆PrP. First, ∆PrP retains the 
secretory signal sequence and the GPI anchor site needed for appropriate targeting to 
the secretory pathway and for attachment for the plasmalemma. Second, ∆PrP 
pathology is suppressed by co-expression of wild-type PrPC, whereas cyPrP induces 
pathology regardless of PrPC expression.  
Cross-linking of cellular prion protein by specific monoclonal antibodies has been 
shown to trigger extensive apoptosis in hippocampal and cerebellar neurons (Solforosi 
et al., 2004). Our in vitro model might be suitable to test a variety of antibodies for 
their capability to induce cell death and to map the regions of PrP accessible to cross-
linking. The mechanisms of cell death could then also be analyzed in order to clarify 
if cell death is induced by a loss of function of PrP, such as mediating a survival 
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signal, or by initiating an apoptotic cascade. Moreover, Solforosi et al. (Solforosi et 
al., 2004) suggested that in prion-infected brains, neuronal loss may occur when 
oligomeric forms of cell surface PrPSc (Lehmann and Harris, 1996; Vey et al., 1996) 
undertake the PrPC cross-linking role.  
With this in vitro model, we have a powerful tool to analyze death or survival 
pathways and, hopefully, to elucidate the physiological function of the cellular prion 
protein.  
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PART II 
 
Efficient prion inactivation, solubilization and facilitation of 
LC-MS/MS analysis of PrPSc by the anionic detergent 
sodium 3-[(2-methyl-2-undecyl-1, 3-dioxolan-4-yl) methoxyl]-
1-propanesulfonate (MPS).  
 
INTRODUCTION 
Protein aggregation and neurotoxicity 
 
Abnormal protein aggregation is a key feature of a number of other neurodegenerative 
diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases and 
amyelotrophic lateral sclerosis (Aguzzi and Haass, 2003; Murphy, 2002; Selkoe, 
2003; Taylor et al., 2002b). These protein aggregates share several physicochemical 
features: a fibrillar morphology, a predominantly beta-sheet secondary structure, 
birefringence upon staining with the dye Congo red, insolubility in common solvents 
and detergents, and protease-resistance. None of the polypeptides implicated in these 
diseases exhibit any primary sequence homology, nor do they derive from similar 
sources. However, non-conservative gene mutations have been identified for each of 
these disorders, contributing to protein misfolding, aggregation and eventual 
deposition in neuronal inclusions and plaques. These diseases lead to extensive 
degeneration of neurons. In Huntington’s disease, neuronal loss is believed to be 
directly mediated through the aggregated state of the huntingtin protein (Bates, 2003; 
Meriin et al., 2002). In other cases (for example the beta-amyloid and alpha-synuclein 
proteins in Alzheimer’s and Parkinson’s disease respectively), presumptive neurotoxic 
oligomeric protein-intermediates, referred to as protofibrils, have been suggested to 
mediate cell death (Lashuel et al., 2002). In prion diseases, the precise role of 
misfolded, aggregated scrapie prion protein in the neurodegenerative process remains 
controversial. The protein-only prion hypothesis of protein replication, initially 
conceived in 1967 (Griffith, 1967) and subsequently refined by Stanley Prusiner 
(Prusiner, 1982) states that the prion (of which PrPSc constitutes the major, if not sole 
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component) is the infectious and neurotoxic agent. However, work by Brandner et al. 
(Brandner et al., 1996a) and recently by Mallucci and coworkers (Mallucci et al., 
2003) provide evidence in vivo that accumulation of PrPSc in the brain per se does not 
cause neurodegeneration. Rather, this neurotoxicity may be mediated by the 
conversion of the cellular isoform (PrPC) to disease-associated isoforms (PrPSc) 
specifically within or on neurons expressing the prion protein. Or, because PrPSc binds 
PrPC (Horiuchi and Caughey, 1999b), it may cause a loss or alteration of the 
physiological function of PrPC. However, postnatally induced Prnp ablation does not 
elicit any phenotype (Mallucci et al., 2002), hence prion pathology is unlikely to come 
about by a loss of PrPC function.  
A general mechanism for neurotoxicity in all neurodegenerative diseases based on 
protein aggregation has recently been suggested (Bucciantini et al., 2002; Kayed et 
al., 2003). Bucciantini and colleagues were able to demonstrate that aggregation of 
non-disease associated proteins exhibit inherent cytotoxicity. Moreover, it has 
recently been demonstrated that different types of soluble amyloid oligomers 
potentially share a common structure that is recognized by a single antibody 
irrespective of the primary amino acid sequence (Kayed et al., 2003). The binding of 
this antibody neutralizes the cytotoxic effects of these oligomers, again suggesting a 
common mechanism of toxicity for all these oligomers. However, despite this recent 
progress, understanding of the precise pathophysiological mechanisms that eventually 
lead to the death of neurons is currently lacking.  
 
Proteomic analysis in neuroscience 
 
Recent advances in instrument technology, bioinformatics and molecular biology 
(genomics, proteomics, functional genomics) are making it possible to simultaneously 
analyze entire complements of genes expressed in particular cells or tissues. 
Complementary insights into biological or disease related processes have been 
obtained by proteomic studies. The field of neuroscience is particularly well suited to 
analysis with these new techniques, given the complexity of neuronal signaling and 
the diversity of cellular responses.  
The concept of the proteome was recently defined as “The entire protein complement 
expressed by a genome or by a cell or tissue type” (Wilkins et al., 1996). A two-step 
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process generally drives proteome analysis: protein sample preparation (i.e. 
purification, separation) and the subsequent analysis by mass spectrometry (MS). The 
broadest proteome coverage is probably obtained from a combination of 
multidimensional fractionation and advanced MS instrumentation. Multidimensional 
separations are a prerequisite for the detection of lower abundant proteins. Several 
protein fractionation methods have been developed such as two-dimensional 
polyacrylamide gel electrophoresis 2D-PAGE (Hanash, 2001) or multidimensional 
protein identification technology (MudPIT) (Washburn et al., 2001) and applied to 
research in neurodegenerative diseases (Butterfield and Castegna, 2003; Zou et al., 
2003). Multidimensional chromatography in conjunction with isotopic labeling allows 
to identify and at the same time quantify proteins in complex mixture (Gygi et al., 
1999; Han et al., 2001; Ideker et al., 2001; von Haller et al., 2001). The prototypical 
method to generate quantitative protein profiles based on stable isotope affinity 
tagging and MS is the isotope-coded affinity tag (ICAT) reagent method (Gygi et al., 
1999). This method makes use of the facts that pairs of chemically identical analytes 
of different stable-isotope composition can be differentiated in a mass spectrometer 
owing to their mass difference, and that the ratio to signal intensities for such analyte 
pairs accurately indicates the abundance ratio for the two analytes. A typical 
experiment compares the protein expression levels of two samples. After appropriate 
purification each fraction is tagged with either of the two available ICAT reagents that 
specifically label cysteine residues (13C0/13C9). After terminating the labeling reaction, 
the two samples are pooled and tryptically digested. The pooling prevents an 
alteration of the protein ratios that may occur due to uneven sample handling. 
Depending on sample complexity, the resulting peptide mixture is fractionated by 
multi-dimensional chromatography and purified through avidin affinity columns. 
Finally, labeled peptides are analyzed using tandem mass spectrometry. Ad-hoc 
developed software (i.e. SEQUEST, INTERACT, XPRESS) (Han et al., 2001) allows 
automated identification, quantification, and data mining of every peptide (Fig. 27).  
The ICAT technology is also well suited to analyze protein interaction studies. In such 
experiments, accurate quantification by means of stable-isotope labeling is not used 
for protein quantification per se; instead the stable isotope ratios distinguish between 
the protein compositions of two or more protein complexes. It would therefore be well 
suited to compare prion-infected brain to non-infected brain, and subsequently, to 
identify components of protein aggregates and to assess whether these represent 
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factors that are involved in PrPSc conversion and aggregation or play a role in the 
disease-related neurodegenerative processes. In conjunction with mass spectrometry, 
this technology allows for detection of low abundant proteins. Therefore it might be 
suitable for establishing a diagnostic test that allows screening for low prion titer in 
blood or urine. The currently available diagnostic tests for prion diseases can only be 
made by analysis of biopsy or autopsy material, thereby detecting protease resistant 
PrPSc or PrP27-30 (the protease resistant core after PK digestion) in tissue samples by 
Western blot analysis or immunohistochemistry.  
 
 
 
Figure 27. The ICAT reagent strategy for quantifying differential proteins. Two protein mixtures 
representing tow different cell states are treated with the isotopically light (green) or heavy (red) ICAT 
reagents, respectively. The labeled protein mixtures are then combined and proteolyzed; tagged 
peptides are selectively isolated, analyzed by MS, quantified and identified (Tao and Aebersold, 2003). 
 
Limitation and drawbacks of proteomics of neurodegenerative diseases 
 
However, the application of powerful proteomic technologies on neurodegenerative 
disease research is often impaired by the insoluble nature of the disease-associated 
protein aggregates. Harsh conditions, e.g. 80% formic acid treatment of A-beta 
amyloid plaques (Harigaya Y. et al., 1995) and the exposure of PrPSc to Gdn-HCl or 
urea (Prusiner et al., 1993; Prusiner et al., 1981), are required to denature and 
solubilize the proteins. In the case of prion diseases these steps are frequently required 
to inactivate the infectious agent prior to sample processing and analysis out of BSL3 
containment facilities. Perhaps more significantly, these conditions are incompatible 
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with subsequent sample fractionation and processing. In particular, liquid 
chromatography tandem mass spectrometry (LC-MS/MS) based analyses require 
specific proteolytic cleavage by endopeptidases such as trypsin. However, even 
slightly unfavorable conditions will either inhibit protein cleavage, or favor non-
specific cleavage events, hampering MS analysis. Thus, the mentioned solubilizing 
agents for protein aggregates are required to be neutralized, significantly diluted, or 
fully removed by time-consuming additional procedures prior to further biochemical 
processing and analyses.  
 
Outline of this work 
 
To enable and facilitate our mass spectroscopic studies of PrPSc aggregates in prion 
disease, we sought to establish procedures that would allow us to analyze protein 
aggregates and associated factors in a reproducible manner using ICAT labeling and 
LC-MS/MS. Based on experiments with aggregated PrPSc, we have tested different 
denaturing agents to solubilize aggregated proteins and finally developed a method 
using the novel surfactant sodium 4-[2-methyl-2-undecyl-1, 3-dioxolan-4-yl) 
methoxyl]-1-propane sulfonate (RapiGest™, Waters; in this study referred to as 
MPS). MPS is a mild denaturant that facilitates solubilization and unfolding of 
proteins, especially hydrophobic proteins/peptides, rendering them more amenable to 
cleavage without inhibition of commonly used proteases. The reagent is acid 
sensitive, thereby allowing for easy removal from the analytes, and does not interfere 
with downstream post preparation methods such as HPLC or LC-MS/MS.  We 
demonstrate that MPS allows for solubilization of inherently insoluble PrPSc and 
allows it to be accessible for proteomic analysis by mass spectrometry. Additionally, 
MPS renders partially proteinase K resistant PrPSc PK-sensitive and reduces prion-
infectivity titers by several orders of magnitude (approximately 6 logs LD50). 
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RESULTS 
 
GdnSCN and urea are incompatible with trypsin digestion  
 
We wished to establish a simple protocol that is compatible with currently available 
quantitative proteomics technologies, while addressing the processing of samples that 
contain highly insoluble protein fractions. We therefore assessed the use of a range of 
reagents for their efficacy in solubilization of aggregated prion protein PrPSc, thereby 
conferring accessibility for further proteolytic cleavage.  
For this purpose, 10% brain homogenate of prion infected CD1 mice at terminal stage 
of disease was processed and utilized in a number of ways: Direct exposure of the PK 
treated material to trypsin did not allow cleavage of the PK resistant core of PrPSc as 
assessed by Western blot analysis (Fig. 28a). Next we tested whether GdnSCN or 
urea, both known to disaggregate PrPSc at least partially (Prusiner et al., 1993), were 
capable of rendering cleavage sites accessible to trypsin. As shown in figure 28b, 
trypsin digestion of PK digested PrPSc was incomplete when treated either with 8M 
urea for 2h and 24h or with 6M GdnSCN for 24h. Longer incubation in 8M urea at 
room temperature was even less favorable than 2 hours incubation and resulted in 
reduced tryptic cleavage of PrPSc. This may be due to carbamylation of lysine and 
arginine residues (McCarthy et al., 2003). In this process, urea decomposes to 
isocyanic acid that subsequently reacts with the amino terminus of peptides or with 
the side chains of lysine and arginine residues and results in inhibition of proteolysis 
by trypsin. As strong denaturing conditions (i.e. 6M GdnSCN or 8M urea, 
respectively) were not compatible with the subsequent proteolytic cleavage step, 
GdnSCN treated samples had to be dialyzed against H20 prior to cleavage, and the 
urea concentration had to be adjusted to 1M in the urea-treated samples. To 
circumvent these problems, an agent that would solubilize and unfold proteins, 
without having the incommoding effect of denaturing or inhibiting common 
proteolytic enzymes would be highly desirable.  
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Figure 28. Urea and GdnSCN are incompatible with trypsin digestion. A PrPSc after PK treatment, 
resist to trypsin digestion (lane 2 and 4) independently of PrPSc exposure at RT for 2h to H20 (lane 1 
and 2) or 8M urea (lane 3 and 4). For trypsin digestion, sample containing 8M urea was diluted to 1M 
urea to ensure efficient tryptic digestion. B PrPSc were exposed to either 8M urea for 2h or 24h (lane 7 
and 8) or 6M GdnSCN for 24h at RT (lane 9). After dilution to 1M urea respectively dialysis against 
H2O, samples were digested with trypsin O/N at 37°C. Lane 1, 2 and 3: PrPSc samples prior to 
exposure to PK, detergents and trypsin. Lane 4, 5 and 6: PrPSc samples after PK digestion. Longtime 
exposure of membrane to film. 
 
A novel surfactant “sodium 4-[2-methyl-2-undecyl-1, 3-dioxolan-4-yl) 
methoxyl]-1-propane sulfonate”(MPS) efficiently solubilizes PrPSc
 
MPS, a newly available detergent, was specifically developed to render hydrophobic 
proteins amenable to enzymatic digestion. It is compatible with all common used 
proteases, such as Lys-C, Asp-N and Glu-C endoproteinases, and chymotrypsin. 
Trypsin digestion was shown to be greatly enhanced and accelerated even at MPS 
concentrations of up to 2% (see product description of MPS). 
In order to determine to what extent MPS allowed solubilization of PrPSc, PK-treated 
samples were incubated at RT and at 95°C and exposed to 1 or 2% of detergent. 
Thereafter, the samples were incubated with trypsin at 37°C overnight, and the 
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cleavage efficiency determined by Western blotting (Fig. 29a/b). The cleavage 
efficiency directly correlated with detergent concentrations, incubation temperature 
and time. Incubation at 95°C for 1 hour at a final detergent concentration of 2% 
resulted in almost complete trypsinization of the PK-resistant core of PrPSc, whereas 
incubation at room temperature (data not shown) and low MPS concentrations were 
ineffective (Fig. 29a and b). PK treated PrPSc, remaining after tryptic digestion O/N at 
37°C, could be completely processed by an additional incubation of 6h adding fresh 
trypsin (Fig. 29c, lane2). Detergent concentrations higher than 2% were not tested 
since they are reported to increasingly interfere with subsequent proteolytic cleavage 
(see product description of MPS).  
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Figure 29.  Concentration and time dependent solubilization effects of MPS. A PrPSc was exposed 
to PK and incubated in 1% (lane 2 and 4) or 2% MPS (lane 3 and 5) for 5 or 30min. Thereafter, the 
samples are trypsinized O/N at 37°C. B PrPSc was exposed to PK and incubated in 1% or 2% MPS for 
60min. The samples are trypsinized subsequently O/N at 37°C. C lane 1: PrPSc treated with PK (control 
positive), Lane 2: PrP27-30 exposed to 2% MPS for 60min. Thereafter, it was trypsinized twice. Lane 3:  
PrPSc PK digested, but not exposed to MPS (control positive), lane 4:  After exposure to 2% MPS for 
60min, PrPSc is PK sensitive.  
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MPS reduces prion infectivity 
 
When PrP27-30 is exposed to MPS for 1h at 95°C, PrP27-30 becomes sensitive to PK, 
whereas untreated material still displays PK resistance (Fig. 29c, lane 3 and 4). This 
prompted us to ask whether this PK sensitivity would correlate with a reduction of 
infectivity titers as it has been described for SDS, GdnSCN and urea (Prusiner et al., 
1993; Taylor et al., 1999). To assess whether MPS is able to inactivate prions, we 
performed a mouse bioassay using tga20 mice that overexpress murine PrPC (Fischer 
et al., 1996). One group of mice was inoculated with 30µl of 0.75 x 106 RML 5 that 
had been exposed to 2% MPS at 95°C for 1h. 0.1% SDS as well as PK, that was 
preliminary heat-inactivated, were also present in order to simulate the conditions that 
are used for sample preparation for mass spectrometry analysis (see method and 
material). For control, an age-matched group of mice was inoculated with RML 5 that 
had been digested with PK (50µg/ml, for 30 min at 37°C) in the presence of 0.1% 
SDS. This amount of SDS enhances the PK activity and allows for a shorter 
incubation time of PrPSc in order to become PrP27-30. The control group was to 
estimate the reduction of the titer by exposing PrPSc to this low amount of SDS and 
PK treatment. As depicted in figure, the low amount of 0.1% SDS in conjunction with 
PK digest can reduce the titer of prion infectivity by approximately 3 logs. Even more 
important, confirming our solubilization results, 2% MPS in the presence of 0.05% 
SDS is able to reduce infectivity titers by 5-6 logs LD50 (Fig. 30). 
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Figure 30. Infectivity bioassay. A Survival curve of mice inoculated with RML 5 which was 
subjected to different treatments: without/with SDS, without/with RapiGest. B Infectivity titers as well 
as reduction factor were calculated on the basis of y=11.45-0.088* x (x in days). 
 
As the reduction of the titer is close to the detection limit of the bioassay, we thought 
to further reduce the infectivity titer by incubating RML 5 24 h at 95°C instead of 1h 
at 95°C in 2% MPS or 4% MPS. Prior to inoculation in tga20 mice, the presence of 
PrPSc in the inoculation samples was checked by Western blot (Fig. 31). Surprisingly, 
PrPSc was no longer detectable after 12 h of incubation. We then performed an 
experiment to analyze if MPS could be responsible for the loss of PrPSc. Therefore, 
we compared RML 5 incubated in MPS to RML 5 incubated in H2O for 12 h at 95°C. 
The PrPSc signal also vanished when it was exposed to H2O for 12 h at 95°C. Was PK 
inactivation at 95°C for 30min insufficient and did PK therefore retain some activity 
that was able to degenerate PrPSc?  RML 5 was exposed to H2O alone, H2O and heat-
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inactivated PK, or H2O, SDS and heat-inactivated PK. These three samples were then 
heated at 95°C for 1h and 12h. As can be seen in figure 31, incubation for 1 h at 95°C 
seemed not to reduce the PrPSc content, however PrPSc disappeared completely after 
12h incubation at 95°C. Not only PrPSc disappeared, but also all other proteins were 
lost after 12h incubation at 95°C illustrated in figure by the disappearance of actin. In 
order to exclude that tryptic-digested PrPSc loss is due to its exposure to 37° 
overnight, PrPSc was incubated in MPS only at 37°. PrPSc was still fully detectable 
after this treatment (data not shown).  
 
 
Figure 31. PrPSc signal on Western blot disappeared after 12h incubation at 95°C. A Western blot 
for PrP and actin after incubation in 2% MPS at 95°C for 1, 12 and 24h. B Western blot for PrP after 
incubation in H2O for 1 and 12h at 95°C. 
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PrPSc tryptic peptides are readily detected by mass spectrometry 
following MPS treatment  
 
To determine if tryptic peptides of PrPSc are detectable by LC-MS/MS, we first 
enriched for PrPSc by the sodium phosphotungstic acid precipitation (NaPTA) assay 
which selectively precipitates PrPSc and not PrPC (Safar et al., 1998; Wadsworth et al., 
2001). The resultant pellet was treated with PK to remove contaminating PK sensitive 
proteins that co-precipitate with PrPSc. Following PK digestion the protein pellet was 
resolubilized by short heating in the presence of MPS. As can be seen in figure a, 
following SDS-PAGE and silver staining, three bands are visible at the molecular 
weight of PrP27-30, as would be expected for the proteolytic core of PrPSc. Analysis of 
this material by mass spectrometry revealed that we were able to detect tryptic 
peptides with a total coverage of approximately 60% of the amino acid sequence of 
PrP27-30 (Fig. 32b).  
 
 
Figure 32. PrPSc peptides are detected by mass spectrometry after treatment with MPS. A 
Silverstaining of precipitated and PK treated infectious brain homogenate. B Peptides of material in A 
(in blue) detected by mass spectrometry cover 60% (of 84% detectable) of the amino acid sequence of 
PrP27-30. 
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MPS is compatible with ICAT labeling 
 
To identify components of protein aggregates and to assess whether these represent 
factors that are involved in PrPSc conversion and aggregation, we utilized the 
quantitative method based on stable-isotope labeling to distinguish between the 
protein compositions of two or more protein complexes.  In the case of a sample, 
containing a protein complex, and a control sample, containing only contaminating 
proteins, the method can distinguish between true complex components and 
nonspecifically associated proteins. In addition, ICAT technology allows protein 
quantification that could be exploited to quantify PrPSc molecules in a given sample.  
We therefore tested whether the solubilization of proteins with MPS is compatible 
with the ICAT technology. In the standard protocol the proteins are dissolved in a 
basic Tris-HCl/EDTA (pH 8.4) buffer containing 6M urea and 0.05% SDS that 
guarantee for an efficient protein solubilization. For the subsequent tryptic digest of 
the proteins, the sample has to be diluted at least 6-fold to reduce the concentration of 
urea to equal or less than 1M. As this step may interfere with efficient processing of 
aggregated proteins, we assessed whether urea could be replaced by MPS in the ICAT 
labeling buffer. For this purpose equal amounts of bovine serum albumin (BSA) were 
dissolved in labeling-buffer either containing 6M urea or 2% MPS. The proteins were 
solubilized at room temperature, reduced and differentially labeled with the light 
(sample in urea-buffer) or heavy (sample in MPS) ICAT labels. The reaction was 
stopped with DTT. The samples were then combined and digested with trypsin after 
diluting the sample to a final concentration of 1M urea. The efficiency of the labeling 
process and of the tryptic digest was monitored on a silverstained gel (Fig. 33a and b).  
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Figure 33. Silverstaining of samples digested with trypsin. A Silverstaining of BSA protein, before 
(lane 2) and after ICAT labeling using either a buffer containing urea (lane 3), or a buffer containing 
MPS (lane 4). B Silverstaining of BSA protein, before (lane 3) and after ICAT labeling using buffer 
containing MPS (lanes 5 and 7). Lane 2, 4 and 6 are empty lanes.  
 
The digested peptides were affinity purified and prepared for LC-MS/MS analysis (for 
details see Materials and Methods). As depicted in figure 34 b and c, the measured set 
of light and heavy-labeled BSA peptides appeared with the same relative abundance 
(i.e. a ratio of 1:1) indicating that the labeling-efficiency was identical for both 
samples. These results were confirmed by exchanging light and heavy labels and 
repeating the entire procedure. Next, we replaced urea by MPS in both samples. The 
BSA samples were incubated either at RT or at 95°C in 2% MPS (final concentration 
1.4%) for 60 minutes, differentially labeled and finally combined as described above. 
The tryptic digest was performed without sample dilution and the peptides were 
processed as described above. LC-MS/MS analysis revealed that the relative 
abundance of light and heavy labeled peptides was unchanged, indicating that the 
labeling efficiency was equal and that MPS did not interfere with mass spectrometric 
analysis (Fig. 34c). In addition, a slightly better sequence coverage (Fig. 34a) for BSA 
was obtained (with a tendency to generate fewer peptides with a missed tryptic 
cleavage site) when compared to the previous experiments indicating that urea can be 
replaced by MPS in any ICAT experiment without any constraints.  
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Figure 34. MPS is compatible with ICAT labeling. A Protein sequence of the BSA protein. Cystein 
residues are labeled in orange, identified peptides are shown in blue (a total of 19 to 21 (76-84%) out of 
25 (100%) possible cystein-containing peptides were detected). Peptides identified by MPS only 
incubation are underlined. Missed cryptic cleavage sites are more often observed after incubations with 
urea in the incubation buffer. A more complete digest is obtained when incubation with MPS (data not 
shown). B and C MS-based elution profile for two representative peptides from a sample labeled in 
buffer containing urea or MPS (B, silverstain fig. 33 A), or MPS only (C, silverstain fig. 33 B). Note 
the precise co-elution of light and heavy peptides and the conserved 1:1 ratio in both experiments.  
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Quantitative analysis of protein samples enriched for PrPSc using ICAT 
and mass spectrometry 
 
To assess whether we can identify PrP27-30 by LC-MS/MS in more complex protein 
mixtures, we performed a quantitative ICAT analysis by comparing brain 
homogenates from RML 5 inoculated terminally sick C57BL/6 or tga20 mice with 
equally processed brain homogenates from mock inoculated control animals 
(C57BL/6 or tga20 mice) using the established MPS labeling protocol. Prior to MPS 
treatment and ICAT labeling, protein extracts were enriched for PrPSc by differential 
precipitation with sodium phosphotungstic acid (NaPTA) and subsequently digested 
with PK. The protease was then heat-inactivated and the efficiency of the PK digest 
was determined by an anti-PrP Western blot. The PK resistant proteins were 
solubilized in 2% MPS by incubating the samples for 1 hour at 95°C. The RML 5 and 
mock protein samples were differentially ICAT labeled (i.e. mock inoculated: light; 
terminally sick: heavy), and purified as described. The purified peptides were 
separated over a reverse phase column prior to LC-MS/MS analysis. PrPSc could be 
detected in this analysis as judged by an increased abundance of the heavy labeled 
peptide (Fig. 35). A detailed analysis of the LC-chromatogram revealed that the light 
isoform of the cystein-containing peptide was not present in this sample. Additional 
proteins (total of 26) were detected, however all showing an unaltered isotope ratio. 
The only protein that displayed differentially in the two samples was the internal 
positive control PrPSc.  
We have repeated this type of experiments and were able to detect PrPSc in as little as 
100µg of PK (no NaPTA precipitation performed) treated 10% brain homogenate of 
terminally sick C57Bl/6 mouse brains (data not shown).  
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DISCUSSION  
 
Proteome analysis is gradually being applied to human brain samples from patients 
with neurodegenerative diseases or to the brains of transgenic mice that model human 
neurodegenerative diseases. Global profiles of protein expression are established and 
comparative proteome analysis is then performed allowing for identification of 
proteins differentially expressed in physiological and diseased states. Proteomics has 
also been applied to study specific proteins, the function of which may play a role in 
the pathological mechanism of neurodegenerative disease. Lately, several studies have 
been applying the techniques of electrophoresis, coupled with mass spectrometry, to 
specific enzymes in order to identify their role, their mechanism of action and their 
relationship with other proteins in the brain (Brining et al., 1999; Gibb et al., 2000; 
Lund et al., 2001). Several neurodegenerative diseases (e.g. Alzheimer’s, Prion, and 
Huntington’s disease) are characterized by the accumulation of protein aggregates. 
The proteins of these diseases lack any significant primary sequence homology, yet 
their aggregates possess very similar features, specifically, high beta sheet content, 
fibrillar morphology, protease resistance, and relative insolubility. This insolubility, 
however, hampers a more thorough analysis of these aggregates, in order to obtain an 
answer to the impact of these aggregates on neurons (neurotoxicity?) or the 
association with other proteins that might be involved in initiating the precipitation of 
these protein aggregates. The agents used to solubilize these protein aggregates (e.g. 
formic acid, urea, NaOH) are often not compatible with subsequent analysis by MS, 
since they hinder enzymatic digestion to obtain peptides of the aggregates.  In this 
study, we have evaluated a new agent, referred to as MPS, for its solubilization 
efficiency of PrPSc compared to other known agents, that have been shown to 
disaggregate PrPSc, and for its compatibility with MS analysis.  
High molar concentrations of urea and guanidinium have been shown to solubilize at 
least partially PrPSc (Safar et al., 1993). Therefore, we tested these agents for their 
usability in MS analysis. However, beside their limited solubilization efficiency, they 
had to be diluted or eliminated by dialysis prior to tryptic digestion, that represent 
time consuming steps and a risk to loose material. Moreover, diluting out detergents 
risk to propagate re-aggregation of PrPSc (Post et al., 1998). The new agent MPS, a 
mild denaturant agent, that renders proteins accessible to enzymatic cleavage, has 
been shown to solubilize PrPSc at least as good as GdnSCN and urea, and moreover 
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renders PrPSc PK sensitive. As denaturation of PrPSc has been consistently 
accompanied by a reduction in scrapie infectivity (Diener et al., 1982; Prusiner et al., 
1993), we tested MPS for its inactivation activity. Incubation of RML 5 in 2% MPS at 
95°C reduced infectivity by a factor of 5-6 logs LD50. However, it is questionable if 
MPS is the only factor that contributes to this reduction in infectivity, considering the 
results of incubation of RML 5 for 12h at 95°C. Independently of the presence of any 
detergent, PK or trypsin, proteins were lost after an incubation of RML 5 in H20 for 
12h at 95°C. In order to test the impact of heating on the loss of infectivity, an 
identical bioassay should be performed using H2O in place of MPS. Additionally, 
samples that were treated with SDS also displayed a reduction of 3 logs LD50. This 
reduction is most likely due to enhanced PK activity in the presence of SDS, since it 
has been reported in several publications that only high concentrations of SDS 
significantly reduced the infectivity titer (Prusiner et al., 1993; Taylor et al., 1999). 
Moreover, it has been shown that the scrapie agent can be inactivated by prolonged 
protease K activity (Neary et al., 1991).  
Furthermore, we have shown that the agent allows the detection of PrPSc tryptic 
peptides by MS. We found coverage of 60 % of the amino acid sequence of the PK 
resistant core of PrPSc. The possible sequence coverage is 83,5%, since the C-terminal 
fragment is expected to contain the GPI anchor. 23.5% of coverage of the amino acid 
sequence was missing because of the size of some peptides that is too small to be seen 
by the applied type of MS-analysis. Additionally, the new agent is compatible with 
the ICAT labeling and subsequent tryptic digestion to obtain the cystein containing 
and thus labeled peptides. Labeling in MPS was at least as good as labeling in urea. 
Quantitative analysis of protein samples enriched for PrPSc using ICAT and mass 
spectrometry revealed that PrPSc could be detected differentially in the infected versus 
non infected sample. The amino acid sequence of the prion protein contains two 
cysteins that can be labeled by the ICAT. However, we found only one cystein 
containing peptide. The other cystein containing peptide (amino acids 157-184) was 
probably not identified because of highly branched glycosyl groups linked to aspargin 
residue 181. Twenty-six additional proteins were detected all showing unaltered 
isotope ratio.  However, we have not yet utilized the full potential of the method. The 
twenty-six additional proteins most likely represent the most abundant proteins in a 
PK-digested NaPTA precipitate. The small number of identifications in repeated 
analysis of the same preparation is due to the fact that we did not remove PK-cleavage 
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products and thus the sample complexity might still be relatively high. Furthermore, 
we have not further sub-fractionated the tryptic peptides by strong cation exchange 
(SCX) chromatography, which would again allow for the detection of proteins of 
lower abundance. Considering the difficulties in fully reconstituting continuous PrP 
conversion reactions with the purified PrP isoforms, it is tempting to conclude that 
there may be important conversion co-factors that remain poorly understood 
(DebBurman et al., 1997; Horiuchi and Caughey, 1999a; Saborio et al., 1999). 
Therefore, the improvement of detection and identification of low abundant proteins 
in PrPSc containing samples is crucial, since it might allow identifying such co-factors 
important for conversion and infectivity of the prion protein. In the case of the prion-
infected material, however, sample processing and sub-fractionation of the material 
has to be done in contained laboratories in which some of these expensive platforms 
may not be available. Unfortunately, the inactivation of high titers of prion infectivity 
by the MPS procedure is not complete and thus sample handling cannot be 
accomplished outside the biosafety facilities.  
Prion diseases are usually diagnosed clinically and confirmed by post-mortem 
histopathological examination of brain tissue. Presently, the most widely used 
diagnostic tests exploit the relative protease resistance of PrPSc in brain samples to 
discriminate between PrPC and PrPSc, in combination with anti-PrP mediated detection 
of the proteinase K-resistant part of PrPSc (PrP27-30) by Western blot or ELISA. 
However, no diagnostic test exists for the detection of prion diseases in live animals 
or humans. Due to the slow kinetics of accumulation of PrPSc and consequent low 
abundance of PrPSc in the pre-clinical stage of disease, the detection of the disease 
early in the incubation period is rendered very difficult. Mass spectrometry analysis 
allows femto- to attomole sensitivity and a high mass accuracy (Figeys et al., 1996; 
Valaskovic et al., 1996; Vorm and Roepstorff, 1994), thus ideal to detect low 
abundant PrPSc. Our established protocol using MPS could therefore be used for 
detection of PrPSc preferentially in easy accessible material such as urine and blood. 
Moreover, the ICAT labeling of PrPSc will allow for absolute quantification in 
combination with an internal standard. MPS enables a single buffer assay crucial for 
quantification, since it avoids excessive handling of samples and therefore loss of 
sample. 
Another possibility of early diagnostics includes the finding of surrogate markers 
other than PrPSc. Comparative proteomic is widely used to detect differences in the 
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expression pattern of proteins between healthy and diseased organisms (Langen et al., 
1999; Stoeckli et al., 2001). Such protein profiling might be helpful in identifying 
surrogate markers in blood or urine in the case of prion diseases. Our protocol might 
as well be useful for the application in finding surrogate markers in urine and blood 
using proteomics in prion diseased individuals. 
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METHODS AND MATERIALS 
 
Construction and production of lentiviral vectors  
 
Construction – The construction of the lentiviral vectors encoding PrP, ∆PrP and Dpl 
was performed using pCCLsin.PPT.CMV.EGFP.Wpre. The cDNA of PrP, ∆PrP and 
Dpl were obtained by PCR using primers containing the restriction sites BamHI and 
SalI (PrP- and ∆PrP - Primers: 5’-CGC GGA TCC AAT TTA GGA GAG CCA AGC 
AGA-3’; 5’- ACG CGT CGA CCA CGA GAA TGC GAA GGA ACA-3.Dpl-
Primers: 5’- ACG CGGT CGA CAT TGA TCT TTA CTTT CAC AAT GAA – 3’; 
5’- CGC GGA TCC ATT CAC CAT GAA GAA CCG GCT-3’). The transfer 
construct was digested with BamHI and SalI and the different cDNAs were ligated 
into the transfer construct and fused to the IRES.eGFP.  
 
Production - The lentivirus vector was produced by co-transfection of human kidney 
293T cells on 15cm plates with 30µg of transfer construct (gift from Prof. L. Naldini), 
22.5µg of packaging plasmid (pCMV∆8.91), and 5µg of envelop plasmid (pMD.G) 
(kindly provided by Prof D. Trono, University of Geneva Medical School, Geneva, 
Switzerland) by calcium- phosphate precipitation. After 14-16 hours, the medium was 
replaced with fresh media. After 48h respectively 72h, the conditioned medium was 
harvested, low-speed centrifuged, and filtered through a 0.45µm-pore-size filter. The 
viral vector stock was then concentrated by ultracentrifugation at 50000g for 1.5h. 
After the ultracentrifugation, the pellet was resuspended in sterile PBS and stored at 
4°C. After the second collection of media and subsequent ultracentrifugation, the viral 
vector stocks were pooled and subjected to a second ultracentrifugation. The final 
pellet was suspended in sterile PBS, and aliquoted and stored at –80°C. An aliquot 
was used for p24 antigen detection by an enzyme-linked immunoabsorbent assay kit. 
Another aliquot was used for the titration of the viral vector stock. T293 cells were 
transduced with serially diluted supernatants. 
 
Histopathology 
Organs were fixed in 4% paraformaldehyde in PBS (pH 7.5), paraffin-embedded, and 
cut into 2µm sections. Brain sections were stained with hematoxylin-eosin, Luxol-
 
 
 
Nissl, and with commercial antibodies to phosphorylated neurofilament (Sigma). 
Antibody stainings were visualized using a peroxidase-anit-peroxidase method.  
 
ICAT labeling 
Bovine serum albumin (BSA; Sigma) or NaPTA precipitated samples were labeled 
either in urea (8M urea, 0.125% SDS, 50mM Tris-HCl pH 8.3, 0.5M EDTA) or in 
RapiGest labeling buffer (2% RapiGest SF, Waters; 50mM ammonium bicarbonate, 
50mM Tris-HCl pH 8.3, 0.5M EDTA). Prior to the labeling, NaPTA precipitated 
samples were digested with 50µg/ml PK in the presence of 0.1% SDS for 30min at 
37°C and thereafter heated at 95°C for 10min to inactivate PK. Additionally, prior to 
the labeling, proteins were reduced with 10mM TBP at 37°C for 30min. The labeling 
reaction was performed with either light or heavy label for 2h at RT and quenched 
with 10mM DTT. Light labeled and heavy labeled samples were combined and 
digested with trypsin O/N at 37°C. In the case of labeling in urea, the sample was 
diluted to a final concentration of 1M urea.  
 
Immunocytochemistry 
Cells on coverslips were fixed in 4% paraformaldehyde, blocked with 10% fetal calf 
serum, permeabilized if required with 0.1% Tween 20 in PBS containing 1% BSA, 
and incubated with primary antibody in blocking solution (1% BSA/PBS) for 1h at 
RT or O/N at 4°C. Subsequently to rinsing with PBS, cells were incubated with 
secondary antibody (anti-rabbit Alexa 546 or anti-mouse Alexa 546) in blocking 
solution for 1h at RT. Prior to mounting, cells were stained with Dapi. Cells were 
analyzed by fluorescent light microscopy (AxioM200, Zeiss) or confocal microscopy 
(Leica). 
 
Immunoprecipitation assays 
Myelin, spinal cord and cells were lysed in 0.5% Triton-X 100, 150mM NaCl, 50mM 
Tris-HCl pH 7.4, 5mM EDTA and protease inhibitors. The lysates were incubated 
with anti-PrP (6H4) antibody coated paramagnetic beads (Dynal) for 1.5h at RT. The 
beads were washed twice with lysis buffer and once with PBS. The proteins were 
dissociated from the beads by addition of SDS sample buffer and boiling for 5min, 
 92
 
 
 
prior to being separated on a 4-20% SDS-PAGE (Novex precast gel, Invitrogen) and 
transferred to nitrocellulose membrane. 
 
Infectivity bioassay  
To test if, and to what extent, enhanced Proteinase K (Sigma) activity can reduce 
infectivity, 50 µl infected murine brain homogenate  (10% RML 5) were added to 
37µl of 0.2% SDS (final concentration: 0.09%). Of these 87µl, 10µl were diluted 
10’000x (by sequential dilution). After the dilution, 4 tga20 mice were inoculated 
intracerebrally (30µl/mouse). The presence of PrPSc in the sample was checked on a 
Western blot prior to inoculation. The remaining 76µl were further processed by 
digestion with 4µl of Proteinase K (PK) (1mg/ml; final concentration is 50µg/ml) at 
37°C for 30min. The Proteinase K was then inactivated by incubating the sample at 
95°C for 30min.. Complete digestion of PrPSc in the sample to PrP27-30 was tested by 
Western blot. 10µl of the resulting sample were diluted 20x into 190µl PBS, and 4 
tga20 mice were inoculated i.c. (30µl/mouse).  
To test if, and to what extent, the presence of 0.09% SDS (Sigma) can reduce 
infectivity, 37µl of 0.2% SDS and 4µl of PK (1mg/ml) were pooled and incubated at 
37°C for 30min followed by an incubation at 95°C for 30min to inactivate PK. The 
sample was then spiked with 50 µl of 10% RML 5. 10µl of the sample were diluted 
10’000x (by sequential dilution). 4 tga20 mice were inoculated intracerebrally 
(30µl/mouse). Also here, the presence of PrPSc is checked on a western blot. To the 
remaining 80µl, an equal amount of 4% RapiGest was added (final concentration is 
2% RapiGest) and incubated for 60min at 95°C. Subsequently, 10µl of the sample 
were 20x diluted and 4 tga20 mice inoculated (30µl/mouse). The effect of RapiGest 
on PrPSc in the presence of inactivated PK and SDS is tested on a western blot prior to 
inoculation. Incubation time until development of terminal scrapie sickness was 
determined, and total infectivity titers were calculated using the relationship y=11.45-
0.088x, where y is the LD50 and x is the incubation time (days) to terminal disease. 
 
Isolation of myelin 
Myelin from mouse brain was purified essentially as described by Norton and Poduslo 
(1973). In brief, tissue homogenates of 5% (w/v) were prepared from brain in 0.32M 
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sucrose. Some of the homogenized brain was stored at –80°C. The rest was layered 
over 0.85M sucrose, centrifuged at 75000g for 30min. The crude myelin was collected 
from the interface, suspended in water and centrifuged at 75000g for 15min. The 
resultant pellet was osmotically shocked in deionized water to remove contaminants 
from within myelin vesicles, and centrifuged twice at 12000g for 15min. The pellets 
were suspended in 0.32M sucrose, layered over 0.85M sucrose, and centrifuged at 
75000g for 30min. The myelin was again collected from the interface, resuspended in 
deionised water and pelleted at 75000g for 15min to remove residual sucrose. The 
myelin was resuspended in H2O and stored at –80°C.  
 
Primary cell cultures 
Cerebellar granule cells were isolated from 7-days-old mice as describe previously 
(Schousboe et al., 1989). Neurons were plated onto 100µg /ml (250 µg /ml of for 
glass surfaces) poly-L-lysine coated dishes at a density of  1 x 106 cells/ml and 
cultured in Eagle’s basal medium (GIBCO) supplemented with 10% heat-inactivated 
fetal calf serum, 25mM KCl, 2mM L-glutamine, 100 units/ml penicillin, and 
100µg/ml streptomycin. To prevent growth of glial cells, cytosine arabinoside (10µM) 
was added to the cultures 24 hours after seeding. Glial fibrillary acid protein-positive 
cells were < 5%.  
Mixed glial cell cultures containing oligodendrocytes and astrocytes were produced 
from 1-day-old neonatal mice as describe previously (Trotter et al 1989, McCarthy 
and de Vellis, 1980). Cultures were prepared with high-glucose Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 10% fetal bovine serum and replenished, 
on day 4 and every 3-4 days thereafter for 10 days, with DMEM plus 10% heat-
inactivated horse serum. Oligodendrocytes were purified from mixed glial cultures by 
differential detachment, and negative selection of microglia by adherence to 
hydrophobic plastic. Purified oligodendrocytes were then plated onto either a glass or 
plastic culture chambers coated with 100µg/ml and 10µg/ml poly-L-lysine, 
respectively. Oligodendrocyte precursor cells were expanded with PDGF and FGF 
supplemented SATO medium for 2 days and subsequently differentiated with 1% 
horse serum supplemented SATO medium. After 3 days of differentiation, cells were 
washed with PBS and homogenized in lysis buffer (0.5% NP40, 0.5% sodium 
deoxycholate, protease inhibitors (Roche Molecular Biochemicals) in PBS). 
 94
 
 
 
Homogenate was then incubated on ice for 30min and centrifuged at 10000rpm for 
15min at 4°C. Equal amounts of lysate were then processed for immunoblotting. 
 
Raft preparation 
50 µg of myelin membrane preparation was added to 1.5 ml 20 mM CHAPS or 1% 
Triton X-100 in TNE (25 mM Tris-HCL pH 7.8, 150 mM NaCl, 5 mM EDTA) 
containing protease inhibitors (Complete, Mini; Roche) and incubated on ice for 30 
minutes. 3 ml OptiPrepTM (Axis Shield, Oslo, Norway) was added giving a final 
concentration of 40% OptiPrep and 30% OptiPrep (10 ml) and 5% OptiPrep (2.3 ml) 
was carefully overlayed. The discontinues gradients were centrifuged for 14 h at 
23.400 rpm (4°C) in a Ti 32.1 rotor (Beckman) and 11 fractions of 1.5 ml was 
collected from the top.  
 
Semi-thin sections and electron microscopy 
Mice were perfused with ice cold 4% PFA/3% glutaraldehyde, brain and spinal cord 
were removed and immersed in the same solutions and kept at 4° until processing. 
Tissues were embedded in Epon, semi-thin sections were cut and stained with 
toluidine blue or used for electron microscopy.  
 
Sodium phosphotungstic acid precipitation (NaPTA) 
NaPTA precipitation was performed as described (Safar et al., 1998; Wadsworth et 
al., 2001). In brief, 10% (w/v) homogenates from infected or non-infected murine 
brains were prepared in 0.32M sucrose. Gross cellular debris were removed by 
centrifugation at 1000rpm for 1 min in a microfuge (Eppendorf). 500µl of the 
resultant supernatant was mixed 1:1 (v/v) with 4% (w/v) sarkosyl (laurylsarcosine 
sodium salt; Sigma) prepared in PBS pH 7.4 and incubated for 15min at 37°C with 
constant agitation. Samples were adjusted to final concentrations of 50units/ml 
benzonase (benzon nuclease; Merck) and 1mM MgCl2 and incubated for 30min at 
37°C with constant agitation. Subsequently, samples were adjusted with 81.3µl of 
pre-warmed and less than two-week-old NaPTA-stock solution (4% NaPTA/170mM 
MgCl2, pH 7.4, prepared in H20 and titrated to pH 7.4 with H20). Samples were 
incubated at 37°C for 30min with constant agitation prior to centrifugation at 
14000rpm (15’800xg) for 30min in a microfuge prewarmed at 37°C (Eppendorf). 
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After careful isolation of the supernatant, the pellet was resuspended to 20µl final 
volume with PBS containing 0.1% (w/v) sarkosyl pH 7.4. Thereafter, resuspended 
pellet was PK digested (50µg/ml) at 37°C for 45min and heat inactivated for 30min at 
95°C. RapiGest (Waters) was added to the sample at a final concentration of 2%. The 
sample was then incubated at 95°C for 1h and was further processed by tryptic 
digestion or ICAT labeled followed by tryptic digestion at 37°C O/N. Sample was 
then purified over SEPAK column and speed-vacuum dried. RapiGest was finally 
removed by acidic cleavage and the sample was analyzed using LCQ ion trap mass 
spectrometer (ThermoFinnigan, San Jose, CA). 
 
Titration of virus 
150000 T293 cells/ well in a 24 well-plate were seeded in 500µl of DMEM and 10% 
FCS. Serial dilutions of concentrated virus stock were prepared in a 96 well plate:  5µl 
of concentrated virus were added to 200µl PBS and mixed thoroughly. 50 µl from this 
dilution were diluted in the next well and consequently diluted in 6 further wells 
(dilution factor 300000). Of each dilution 10µl were added to the seeded T293 cells. 
After 48h, cells were trypsinized and fixed in 4% paraformaldehyde for at least 
20min. The fixed cells were transferred to FACS tubes and analyzed for eGFP 
positive cells by FACS on a four-color FACSCalibur flow cytometry (Becton 
Dickinson). Titers were determined according to following formula: (%GFP positive 
cells x dilution factor x number of cells in assay)/1000. 
 
Western blot 
Lysates were run on SDS-PAGE (4-20% precast gel, Novex) and blotted on 
nitrocellulose membranes (Schleicher & Schuell, Dassel). Membranes were blocked 
with 5% (w/v) Top Bloc (Juro AG, Luzern) in TBS-T at RT for 1 hr, incubated with 
20ml TBS-T/1% Top Bloc containing the respective antibody at RT under agitation 
for 1 hr, washed 3x10’ in TBS-T, and incubated with 20ml TBS-T/1% Top Bloc and 
secondary antibody at RT under agitation for 1 hr. Membranes were washed 3x15’ in 
TBS-T, and developed using ECL detection reagents. Signals were recorded on film 
and/or quantified using a Kodak Image Station.  
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